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Background: Pathogenesis of reduced bone mass and its relationships with 
hypovitaminosis D in HIV-infected populations are largely unknown. The goals of this 
dissertation were to determine the prevalence of low bone mass and its pathogenesis, 
along with the prevalence of hypovitaminosis D and its effects on bone turnover and bone 
density among HIV-infected Asian adolescents.    
Methods: A multicenter, cross-sectional study was conducted at four pediatric HIV 
centers in Thailand and Indonesia. Perinatally HIV-infected adolescents aged 10-18 years 
receiving antiretroviral therapy with virologic suppression (HIV RNA <400 copies/ml) 
were enrolled. Study assessments included lumbar spine dual-energy x-ray 
absorptiometry, 25-hydroxyvitamin D (25-OHD), intact parathyroid hormone (iPTH), 
bone turnover markers [C-terminal cross-linked telopeptide of type I collagen (CTX) and 
procollagen type I amino-terminal propeptide (PINP)]. Bone mineral density (BMD) and 
bone mineral apparent density (BMAD) Z-scores were calculated based on Thai 
normative reference. Z-scores <-2 was defined as low bone mass. The 25-OHD <20 
ng/ml and iPTH >65 pg/ml were defined as hypovitaminosis D and hyperparathyroidism, 
respectively. 
Results: Of 396 participants, 57% were female and median age (IQR) was 15.0 (13.3-
16.9) years. The prevalence of lumbar spine BMD and BMAD Z-scores <-2 were 16.4% 
and 8.3%, respectively. Z-scores were lower with older age, female sex, body mass index 
<5th percentile, protease inhibitor exposure and CD4+ <15% before ART initiation. 
Increased bone turnover markers were inversely associated with BMD/BMAD Z-scores.  
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Among 394 adolescents who had 25-OHD results, the prevalence of 
hypovitaminosis D, hyperparathyroidism, and both conditions were 21% (95%CI: 17-
25%), 17% (95%CI: 13-20%) and 5% (95%CI: 3-7%), respectively. Adolescents with 
hypovitaminosis D and secondary hyperparathyroidism had the highest median bone 
resorption (CTX: 1610 vs. 1270 ng/l; P=0.04) and bone formation (PINP: 572 vs. 330 
μg/l; P=0.02) markers, and the greatest proportion of low BMD (42 vs. 15%; P=0.01) 
compared to the rest of the cohort. 
Conclusion: Low bone mass was not uncommon in our adolescents. Bone turnover 
dysregulation was associated with reduced bone mass. Hypovitaminosis D complicated 
with secondary hyperparathyroidism was associated with increased bone turnover and 
bone demineralization. Monitoring of bone mass and vitamin D status may be important 
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Advances in antiretroviral therapy (ART) over the past twenty years have led to a 
dramatic decline in disease-associated morbidity and mortality in HIV-infected 
populations, including infant and children perinatally infected with HIV [1-3]. In 
countries where ART is available and accessible, the face of the HIV epidemic has 
changed from a disease with high mortality to that of a chronic illness [4]. Most patients 
achieve sustainable and possibly lifelong viral suppression. As a consequence, the 
numbers of perinatally HIV-infected infants and children entering adolescence and young 
adulthood have been expanding worldwide [5,6]. However, a considerable improvement 
in life expectancy has been accompanied by a growing incidence of non-communicable 
diseases (NCDs) associated with long-term HIV infection and its therapies, including 
adverse bone health, neurocognitive dysfunction, renal diseases, metabolic disorders and 
endocrine diseases [7-15]. The changing spectrum of HIV-associated diseases is a new 
challenge and a major concern in the medical management of this unique population. 
Among the important roles of healthcare providers and clinical researchers are to find 
ways to help these children and adolescents to be able to grow up with HIV with a high 
or comparable quality of life to their healthy peers. 
The pathogenesis and underlying mechanisms of NCDs in the setting of HIV 
infection remain unclear. Both HIV per se and ART have been reported to be associated 
with these complications [7,10-12,16-18]. In addition, persistent immune activation and 
inflammation due to HIV infection may be another contributing factor even in virally 
suppressed patients [19-21]. Importantly, the impact of these factors on NCDs may be 




HIV infection since birth and have experienced ART for a long duration compared to 
HIV-infected adults who acquire HIV infection later in life.  
Although there are several NCDs reported in perinatally HIV-infected adolescents 
[7-15], adverse bone health is a specific concern. Generally, adverse bone health is a term 
used to describe skeletal disorders which are characterized by reduced bone mass, 
deterioration of bone tissue, disruption of bone microarchitecture and compromised bone 
strength [22,23]. Unlike adults, the term osteoporosis in adolescents is defined as having 
low bone mass with a clinically significant evidence of bone fracture [24]. Therefore, to 
prevent the delayed diagnosis and treatment, most pediatricians and researchers usually 
evaluate adverse bone health problem in adolescents by focusing on individuals who have 
low bone mass rather than osteoporosis [24].  
Low bone mass, which is usually evaluated by Dual-energy X-ray absorptiometry 
(DXA) technique and is defined as bone density Z-score less than or equal to -2.0 
standard deviation [24], has been documented in perinatally HIV-infected children and 
adolescents [7-10,25]. Nevertheless, most of the studies were conducted in resource-rich 
and developed countries, with limited data from resource-constrained settings. 
Bone is a dynamic, viable and highly organized connective tissue that is 
continually being remodeled throughout life to maintain the strength and integrity. Bone 
remodeling is a highly coordinated process which requires the synchronized activities of 
2 specialized bone cells, including osteoblasts for bone formation and osteoclasts for 
bone resorption [26,27]. The imbalance activities between these two cells may result in 
the dysregulated bone turnover and bone mass loss [27]. In the setting of HIV infection, 




factors, e.g., malnutrition, hypovitminosis D, physical inactivity; and HIV-related factors, 
e.g., advanced disease, poor virologic status and some specific ART medications, as well 
as persistent immune activation and inflammation associated with HIV infection [7-
10,25,28-37]. Therefore, all of these factors may result in the adverse bone outcomes in 
HIV-infected population. Unfortunately, the pathogenesis of low bone mass among 
people living with HIV, particularly HIV-infected adolescents, has not been carefully 
investigated. 
Hypovitaminosis D is a global epidemic and health problem that has been 
documented in healthy and HIV-infected populations in all age groups and all settings 
[38-41]. Populations who live in countries with low latitude where sunshine is plenty all 
year long, as well as individuals who live in developed countries where vitamin D 
fortified foods are available, demonstrate a high prevalence of hypovitaminosis D [38]. 
Importantly, this condition has been reported to be associated with numerous adverse 
health outcomes, including osteoporosis, cardiovascular disease, diabetes, cancer, 
autoimmune diseases and some infectious diseases, e.g., tuberculosis [42-48]. 
Furthermore, in HIV-infected populations, deficiency of vitamin D has demonstrated the 
association with poor immune responses to ART which may accelerate disease 
progression to AIDS and increase all-cause mortality [49-53]. However, there are limited 
studies evaluating vitamin D status and its adverse consequences among HIV-infected 
adolescents, especially in resource-constrained settings, even though this population is at 
high risk of hypovitaminosis D. 
There are several factors contributing to hypovitaminosis D in people living with 




hypovitaminosis D include age, sex, race and ethnicity, skin pigmentation and body mass 
index; physical factors such as clothing, glass shielding and sunscreens; and 
environmental factors such as geographic location (latitude) and seasonality can influence 
vitamin D status in individuals [47,54-59]. Additionally, HIV-related factors, including 
clinical stage, immunological status, specific types of ART, e.g., efavirenz and boosted 
protease inhibitors, can affect vitamin D synthesis and metabolism [47,57-59]. Since 
previous studies were mostly conducted in HIV-infected youth who live in Western or 
industrialized countries [56,58], inferences may unfortunately not be able to generalize to 
individuals who live in other settings, such as in resource-constrained countries or 
tropical regions where, besides geographic location and seasons, there may be important 
dissimilarities in lifestyles, cultures as well as foods and dietary supplements that must be 
considered.  
Hypovitaminosis D is considered to be a risk factor for adverse bone health. It can 
result in poor bone mineralization, progressive bone loss, and increased osteoporosis risk 
[54]. Although a study in HIV-infected adults found the association between vitamin D 
deficiency and bone loss [42], several studies in adolescents living with HIV did not 
demonstrate a correlation [9,29]. Moreover, there is lack of research study investigating 
the effects of hypovitaminosis D on the pathogenesis of reduced bone mass among this 
population.  
Normally, when vitamin D levels are deficient or insufficient, calcium absorption 
from the gastrointestinal tract is inadequate to meet the calcium requirements to maintain 
normal physiological functions, which include bone metabolism, neuromuscular activity 




the decreased serum calcium concentration causes an increased in parathyroid hormone 
(PTH) secretion by parathyroid glands, which is called secondary hyperparathyroidism, 
in order to restore calcium homeostasis [54]. The main effects of elevated serum PTH 
concentration are to enhance the release of calcium from the large reservoir in bone 
matrix which is indirectly mediated by osteoclasts and results in bone resorption; 
accelerate the active tubular reabsorption of calcium in the kidney; and increase the renal 
production of calcitriol (active form of vitamin D) to enhance the intestinal absorption of 
calcium [54,60]. Therefore, with these mechanisms, hypovitaminosis D along with 
secondary hyperparathyroidism may potentially cause increased bone turnover, bone 
demineralization and bone loss as the adverse consequences [54,60]. However, to date, 
there is limited information regarding the pathologic impacts of hypovitaminosis D and 
secondary hyperparathyroidism on bone turnover and bone mass among HIV-infected 
adolescents, especially in individuals who live in resource-constrained countries.             
Because a great deal of bone mineral deposition and a lifetime peak bone mass 
(PBM) are normally attained during adolescence [61-63] and, importantly, up to 60% of 
the lifetime risk of osteoporosis is attributable to the amount of bone mineral accrued 
through the first two decades of life [64], any harmful factor occurring during this critical 
period may have tremendous adverse effects on bone mass and bone health of these 
individuals. As a consequence, perinatally HIV-infected adolescents who have been 
exposed to factors negatively influencing bone health during puberty are more likely to 
have reduced bone density and compromised adult PBM, a key determinant of bone 
health [30]. Furthermore, these individuals may experience serious detrimental bone 




decades of life [65-68]. Therefore, feasible interventions to prevent bone loss and 
promote bone health for these adolescents should be promptly implemented before the 
























Goals of the dissertation 
Despite the clear clinical significance and public health importance, the 
information regarding the extent of adverse bone health and hypovitaminosis D among 
perinatally HIV-infected adolescents living in resource-constrained countries are limited. 
Moreover, the pathogenesis of reduced bone mass, the associated factors of vitamin D 
status, and the pathological effects of hypovitaminosis D on bone turnover and bone mass 
among this population have not been intensively explored.  
To fill gaps in current knowledge, the goals of this dissertation were to determine 
the prevalence of low bone mass and its pathogenesis, including bone turnover 
dysregulation and chronic immune activation and inflammation by HIV infection, in 
perinatally HIV-infected adolescents. In addition, this dissertation also aimed to assess 
the prevalence of hypovitaminosis D, secondary hyperparathyroidism and their 
pathological effects on bone turnover and bone mass in this population. By focusing the 
study on Asian adolescents who perinatally acquired HIV infection, this dissertation 
would be able to provide useful scientific information that can raise awareness about 
adverse bone health and hypovitaminosis D problems among pediatricians and healthcare 
providers who are taking care of adolescents living with HIV in their clinical settings, 
and would be beneficial for them to develop the strategies to screen and monitor bone 
health and vitamin D status in individuals who are at high risk for bone demineralization 
and vitamin D deficiency, as well as to implement the interventions to prevent bone 






Specific aims  
Accordingly, the specific aims of this dissertation are: 
AIM 1: To determine the prevalence of low bone mass and evaluate its pathogenesis 
among perinatally HIV-infected Asian adolescents with virologic suppression.  
Perinatally HIV-infected Asian adolescents with virologic suppression on ART 
have a high prevalence of low bone mass. Their bone density is much lower than that of 
their HIV-uninfected peers. Dysregulation of bone turnover, reflected in the increases in 
bone resorption and formation markers, and chronic immune activation and 
inflammation due to HIV infection are potential mechanisms of bone demineralization 
among this population. 
 
AIM 2: To assess the prevalence of hypovitaminosis D and hyperparathyroidism, and 
identify their effects on bone turnover and bone mineral density among perinatally HIV-
infected Asian adolescents with virologic suppression.  
The prevalence of hypovitaminosis D and hyperparathyroidism among perinatally 
HIV-infected Asian adolescents with virologic suppression on ART are high. 
Hypovitaminosis D complicated with secondary hyperparathyroidism is associated with 










 Among perinatally HIV-infected adolescents with virologic suppression on ART, 
HIV-specific factors associated with low bone mass include WHO clinical status, 
immunological status, some specific types of ART and duration of ART use. Similar to 
general populations, traditional factors which include hypovitaminosis D, advanced age, 
female sex, low BMI and physical inactivity are potentially associated with reduced bone 
mass. Furthermore, hypovitaminosis D can cause secondary hyperparathyroidism through 
a positive feedback mechanism to maintain calcium homeostasis, which thereafter may 
result in dysregulation of bone turnover and acceleration of bone demineralization among 
this population. A residual chronic immune activation and inflammation by HIV 
infection, which usually persists even in individuals with successful virologic suppression 
on ART, may also aggravate bone turnover dysregulation that may enhance bone mass 
deterioration. The combination of these factors, traditional factors, HIV-specific factors 
and HIV itself, on low bone mass may consequently result in the decreased adult PBM 
and the increased risk of osteoporosis and bone fracture when these adolescents enter 
their fourth or fifth decades of life. The conceptual framework for this dissertation is 










Organization of dissertation 
 This dissertation is composed of five chapters. The first chapter (this chapter) 
provides an introduction and overview of the dissertation by addressing the significance 
of adverse bone health and hypovitaminosis D problems among perinatally HIV-infected 
adolescents, pointing out the gaps in knowledge in this field, summarizes the goals of the 
dissertation, describes the specific aims of the study, and presents a conceptual 
framework for this dissertation.   
 The second chapter reviews the literatures on adverse bone health among children 
and adolescents growing up with HIV. This chapter describes the extent of adverse bone 
health problem among perinatally HIV-infected children and adolescents in different 
settings, explains the pathogenesis, illustrates the risk factors, and discusses the 
consequences of adverse bone health among this population. Furthermore, the second 
chapter summarizes both standard and advanced measurements to assess bone health, and 
updates the management of bone demineralization for this specific population.   
 The third chapter presents a study on adverse bone health and abnormal bone 
turnover among perinatally HIV-infected Asian adolescents with virologic suppression 
that aims to determine the prevalence of low bone mass and evaluate its pathogenesis in 
this population. In addition, this chapter describes the association between dysregulated 
bone turnover and poor bone mass and the relationships of chronic immune activation 
and inflammation with abnormal bone turnover.    
 The fourth chapter presents a study on hypovitaminosis D and 




suppression which aims to assess their prevalence, as well as pathological impacts on 
bone turnover and bone density in this population.  
 The fifth chapter, which is the last chapter for this dissertation, provides the 
summary of the dissertation findings, points out the lessons learned, addresses the public 
health significance of this dissertation, and proposes the future directions for research in 
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Figure 1. Conceptual framework of the dissertation. 
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Adverse bone health is one of the important non-communicable conditions during 
the course of life-long HIV treatment. Adolescence is the critical period of bone mineral 
acquisition for attaining adult peak bone mass. With traditional and HIV-related risk 
factors, adolescents growing with HIV have a greater chance of having impaired bone 
mineral density (BMD). Prevalence of low BMD has been reported in 16-32% of HIV-
infected adolescents from middle-income countries. The deep interaction between the 
immune and skeletal systems, called immunoskeletal interface, is proposed as one of the 
underlying mechanisms of adverse bone health in HIV-infected individuals. Dual-energy 
X-ray absorptiometry (DXA) is a standard tool to assess BMD among HIV-infected 
adolescents. Non-invasive imaging techniques such as quantitative computerized 
tomography (QCT) and quantitative magnetic resonance imaging (QMRI) provide more 
information on true volumetric density and bone microarchitecture. To date, there are no 
paediatric recommendations on the treatment and prevention of adverse bone health. 
Having healthy lifestyle, routine weight-bearing exercises and adequate dietary intake are 
the standard approaches to optimise bone health. There are several ongoing randomised 
clinical trials using pharmacologic treatment options, for example vitamin D, calcium and 









The success of antiretroviral therapy (ART) has turned HIV/AIDS from a disease 
with a high mortality rate to a manageable chronic life-long illness. Treatment with ART 
can lead to restoration of immune function and sustained viral suppression, which in turn 
increases life expectancy for perinatally HIV-infected children and adolescents [1,2]. 
Currently, HIV-infected children are able to grow up and enter adolescence and young 
adulthood similarly to their healthy peers [3]. Yet, these individuals do experience several 
long-term, non-AIDS-related complications that are obstacles to the goal of normal life 
expectancy and quality of life. The emerging non-communicable diseases (NCDs) 
associated with HIV infection and antiretroviral treatment include adverse bone health, 
cardiovascular, liver and renal diseases, and other metabolic and endocrinological 
disorders [3-5]. Among these complications, adverse bone health has been recognised as 
an important area of investigation during the past decade in children and adolescents [6]. 
Since the maximum bone mineral accrual occurs during the first two decades of life [7], 
reduced bone deposition and increased bone resorption during these critical periods can 
lead to serious consequences, in particular, osteoporosis and bone fragility later in life 
[8,9]. This review focuses on current knowledge regarding adverse bone health among 
children and adolescents living with HIV, including the magnitude of problem, 
immunopathogenesis and factors responsible for reduced bone mass, assessment of bone 
health in clinical practices and up-to-date research studies of management strategies to 





Prevalence of low bone mineral density among perinatally HIV-infected children 
and adolescents  
Dual energy X-ray absorptiometry (DXA) is a commonly used technique to assess 
total body and lumbar spine bone mineral density (BMD) in children and adolescents. 
Because adults have already reached peak bone mass (PBM) [7], their BMD is assessed 
using T-scores. In contrast, BMD measurements in growing children need to be 
compared to healthy age-, sex- and race-matched population norms and are reported as Z-
scores. BMD Z-scores less than or equal to -2 are regarded as low bone mass [10]. The 
prevalence of low BMD among perinatally HIV-infected children and adolescents is 
much higher in studies conducted in middle-income countries than that observed in 
resource-rich countries. The variation in prevalence might be explained by the differences 
in HIV clinical staging at time of ART initiation, duration of ART, lifestyles, nutritional 
status, food intake and dietary supplements across studies (Figure 1) [11-16]. 
 
Resource-rich countries  
In a longitudinal study of 66 HIV-infected Dutch children with a median age of 
6.7 years, almost all children (96%) were on ART for a median duration of 3.4 years and 
58% had undetectable plasma viral load. The prevalence of lumbar spine and femoral 
neck BMD Z-scores below -2 were 8% and 4%, respectively. The median BMD Z-scores 
were 0.9 [interquartile range (IQR) -1.6 to 0.1] for lumbar spine and 0.5 (IQR -0.2 to 1.2) 
for femoral neck [11]. A large cross-sectional study was conducted among 350 HIV-
infected adolescents living in the United States and Puerto Rico, with a median age of 




copies/ml. Similar to the Dutch study, the prevalence of low BMD was 7% for total body 
and 4% for lumbar spine. This was higher than the low BMD prevalence in their 
uninfected peers of 2% for total body and 1% for lumbar spine [12]. Likewise, the 
Pediatric AIDS Clinical Trial Group (PACTG) 1045 found that post-pubertal HIV-
infected adolescent males had significantly lower total body BMD (adjusted difference -
0.10 g/cm2; 95% CI -0.16 to -0.04 g/cm2) and lumbar spine BMD (adjusted difference -
0.13 g/cm2; 95% CI -0.23 to -0.04 g/cm2), compared with HIV-uninfected males at 
similar Tanner stage [17].  
 
Middle-income countries 
 There are four reports from Thailand [13,14] and Brazil [15,16]. The prevalence 
of low lumbar spine BMD among HIV-infected Thais was 16–24%. The median ages of 
Thai participants in these studies were 14.3–15.0 years. All of them were receiving stable 
ART for a median duration of 7.0–9.3 years; of whom 90–96% had virological 
suppression [13,14]. In a cross-sectional study among 48 HIV-infected Brazilian 
adolescents with a mean age of 12.7 years, the prevalence of low BMD was 17% for total 
body less head. Almost all participants (96%) were on ART, of whom 58% had plasma 
HIV RNA <50 copies/ml [15]. Another cross-sectional Brazilian study was found a 32% 
prevalence of low BMD (total body and/or lumbar spine) among 74 HIV-infected 
adolescents with a mean age of 17.3 years. Approximately 91% of them received ART 





Pathogenesis of adverse bone health among HIV-infected population    
Bone is a specialised supporting and protecting structure of the body. It contains 
two major components: calcium phosphate, a mineral compound that gives bone strength 
and rigidity; and collagen, a protein that provides a flexible framework [18,19]. Bone is 
not a static structure, but one that constantly undergoes longitudinal and radial growth, 
rebuilding and remodelling throughout the life [18,20].  
Bone remodelling involves bone resorption, by osteoclasts, and bone formation, 
by osteoblasts [18,20].  In general, bone formation predominates bone resorption during 
childhood and young adulthood [20]. Thus, bone mass increases over time and reaches its 
peak during the third decade of life. Subsequently, bone remodelling becomes balanced 
between bone formation and resorption, resulting in stable bone mass with small 
variations [20]. Around 50 years of age, the rate of bone resorption begins to outpace that 
of bone formation, and thus bone mass declines [20].  
 
Changes in bone mass with the course of HIV disease  
In HIV-infected individuals, the physiological regulation of bone remodelling can 
be disrupted by several factors: HIV itself, ART and other HIV-related factors [21-23]. 
Bone mass changes with the course of HIV disease. During the pre-treatment period, 
many conditions, for example wasting syndrome, disrupt immune system function 
through loss of CD4+ T cells and B cells [24,25]. Together with chronic systemic 
inflammation [26], this disturbs bone homeostasis. Untreated individuals tend to have 
raised inflammatory markers and dysregulated bone turnover compared with healthy 




and bone turnover imbalance, a likely cause of bone demineralisation in HIV-infected 
persons.  
After ART initiation, HIV-infected persons usually have improved health status 
and restored immunological system function. Weight is regained and systemic 
inflammation is reduced [30]. However, such individuals may experience transient 
reduced bone mass and worsening of bone health during the first 1-2 years of ART [31-
33]. Possible explanations are poor health status and wasting before ART initiation [21], 
ART causing imbalance of bone turnover [34,35], and time lag between ART initiation 
and improvement of BMD [21,31]. Accelerated bone loss, as much as 2-6%, has been 
demonstrated in HIV-infected individuals on various ART regimens, including tenofovir 
disoproxil fumarate (TDF) [31], efavirenz (EFV) [32], nevirapine [33] and boosted 
protease inhibitors (PIs) [32,33]. In HIV-infected adults, both TDF and PIs, have been 
associated with a 33% increased in osteocalcin (OC), a bone formation biomarker [34]. 
Another study demonstrated that switching to TDF vs. staying on zidovudine resulted in a 
significant increase in both bone resorption marker; C-terminal cross-linked telopeptide 
of type I collagen (CTX), and bone formation markers; OC and procollagen type I amino-
terminal propeptide (PINP), which correlate with reductions in lumbar spine BMD [35].  
 
Immunoskeletal interface on bone health  
In the context of untreated HIV infection, there are two concurrent and important 
alterations in bone health: progressive loss of immune function and accelerated bone 
resorption. Emerging evidences suggests that the immune and skeletal systems are deeply 




[22]. This is called the immunoskeletal interface (Figure 2). There are well-established 
evidence of the association between immune and skeletal systems observed in many 
inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease and 
systemic lupus erythrematosus [36-38]. These immune alterations accelerate the natural 
skeletal ageing process contributing to adverse bone health. 
The immunoskeletal interface can be divided into two aspects: the interactions of 
immune cells with osteoblasts and with osteoclasts. Osteoblastic cells, derived from 
osteoprogenitor mesenchymal stem cells, are able to modulate the immune system by 
regulating the hematopoietic stem cell microenvironment in which immune cells are 
derived [39]. Immune cells can produce cytokine mediators, such as tumor necrotic 
factor-alpha (TNF-), that functions as a potent inhibitor of osteoblast differentiation and 
activity [40]. Osteoclasts are derived from mature cells of monocyte and macrophage 
lineage. Osteoclastogenesis requires the presence of RANK ligand (RANKL) and RANK 
interactions. RANKL is a receptor activator of nuclear factor κβ ligand expressed by 
osteoblastic lineage cells, while RANK is a receptor activator of nuclear factor κβ 
presented on the surface of osteoclast precursors and mature osteoclasts [41]. RANKL is 
recognised as a key osteoclastogenic cytokine and the final effectors of osteoclast 
formation and activity [42-45]. Additionally, it is considered to have important 
immunological functions as a mediator for T cell proliferation and dendritic cell function 
[46,47]. The interactions between RANKL with RANK (RANKL-RANK system) induce 
the formation and differentiation of osteoclast precursors into pre-osteoclasts, which then 
fuse together to form the mature osteoclasts [42,48]. The essential regulatory component 




superfamily and a RANKL decoy receptor. OPG modulates RANKL activity by binding 
itself to RANKL and prevents the RANKL-RANK interaction, resulting in the inhibition 
of osteoclast formation and maturation [42-44,48,49]. A new cytokine, secreted 
osteoclastogenic factor of activated T cells (SOFAT), was recently identified and 
observed to potently induce osteoblastic IL-6 production [50], which in turn stimulates 
osteoclastogenesis independently of RANKL [51].  
B and T cells are critical for preserving bone homeostatis [52]. B cells produce 
OPG in response to T cell co-stimulation [53]. Activated T cells, through the CD40 
ligand and its receptor CD40 on B cells, can promote B lineage OPG production in vivo 
[52]. However, under inflammatory conditions, B cells and activated T cells turn into a 
significant source of RANKL and SOFAT production [50,54-57]. In addition, several 
inflammatory cytokines, including interleukin (IL)-1, IL-6, IL-7 and TNF-, 
overexpressed by immune cells during inflammation are able to drive up RANKL-
dependent osteoclastogensis [58,59]. Taken all together, the osteoclastic bone resorption 





Risk factors for adverse bone health among perinatally HIV-infected children and 
adolescents 
 The causes of adverse bone health among perinatally HIV-infected children and 
adolescents are multifactorial. They can be classified into traditional risk factors and 
HIV-specific factors (Figure 2). The traditional risk factors for low bone mass include 
malnutrition, short stature, low body mass index, delayed puberty, vitamin D deficiency, 
inadequate calcium intake, physical inactivity, smoking and steroid exposure [12-
14,60,61]. HIV-specific factors, including HIV itself, advanced HIV disease, poor 
immunological status, uncontrolled viraemia, exposure to some specific types of ART, as 
well as persistent immune activation and chronic systemic inflammation also play a 
significant role in driving bone loss among this population [11-17,62-70].    
 
Traditional risk factors 
Weight and height are independently associated with bone mass in healthy 
individuals; however, the effects may be exaggerated in the HIV-infected population 
because they usually have significantly delayed linear growth and poor weight gains [71-
74]. Although low vitamin D has been considered a traditional risk factor for poor bone 
health, there is no well-established evidence demonstrating the significant direct 
association between vitamin D deficiency or inadequate vitamin D intake and adverse 
bone health in HIV-infected adolescents [13,14,60]. Similarly, the evidence of inadequate 
calcium intake as a determinant of reduced bone mass is limited and controversial in this 
population [14,60,61]. A cross-sectional study among 19 HIV-infected girls whose 




that suboptimal calcium intake might lead to the increased bone resorption and impaired 
bone mineral acquisition [61]. In contrast, two cross-sectional studies carried out in 
Brazil and the United States did not find such an association [15,60]. Calcium 
supplementation may be only beneficial to individuals with insufficient calcium intake.  
The relationship between weight-bearing physical activity and bone health among 
HIV-infected youth was demonstrated in a few studies [12,15,62]. The challenge of these 
studies is the best measure for physical activity level. Self-report and questionnaires are 
used by some [12,62], while an accelerometer is used by others [15].  
 
HIV-specific factors  
HIV per se is one of the factors for bone abnormalities. Higher prevalence of 
bone demineralisation was reported among treatment-naïve HIV-infected adults 
compared with HIV uninfected controls [75]. HIV infection is related to a high bone 
turnover state, as demonstrated by the disturbances of histomorphometric parameters 
and/or the dysregulation of biochemical markers of bone formation and bone resorption 
[28,29,76]. 
Advanced HIV disease, uncontrolled viraemia and poor immunological status are 
predictors of adverse bone health among HIV-infected children and adolescents [11-
16,63,64]. Individuals with severe clinical symptoms of HIV had a significant 
impairment of BMD, evaluated by DXA [14] and quantitative high-frequency ultrasound 
(QUS) techniques [63]. High plasma HIV RNA also correlated with low bone mass 
[11,12]. A positive correlation between current CD4+ percentage and BMD/ bone mineral 




Several studies demonstrated a significant linkage between ART exposure and 
reduced bone mass [12,13,15-17,62,66-70]. These were either performed in treatment-
naïve patients [31-33,62,65] or treatment-experienced patients who switch treatment 
because of poorly controlled viraemia [69]. Although early loss of bone mass within the 
first 1-2 years of ART initiation has been observed in treatment-naive adults and 
adolescents [31-33,62,65], there are no data in young children. Significant bone 
abnormalities after ART switching have also been demonstrated in children and 
adolescents [69]. Early bone loss is observed during the first 24-48 weeks of TDF but 
remained stable thereafter. Such an effect is, however, not detected among treatment-
experienced children with stable clinical status and controlled viraemia prior to switch to 
TDF [77]. Tenofovir alafenamide (TAF), a prodrug of TDF, has a more favorable bone 
safety profile. Two randomised clinical trials in HIV-infected adults demonstrated 
significantly less bone toxicity (mean change of lumbar spine BMD -1.3 vs. -2.9%, P 
<0.0001; total hip BMD -0.7 vs. -3.0%, P <0.0001) among adults receiving TAF vs. TDF 












Consequences of adverse bone health in perinatally HIV-infected children and 
adolescents 
Childhood and adolescence represent the critical periods for bone mineralisation 
and maturation, and at least 90% of final adult bone mass is achieved during these 
periods [79]. Any factor impairing bone mineral acquisition may diminish bone gain, 
induce bone loss and compromise adult PBM [7,80]. From two meta-analyses, the 
prevalence of osteopenia and osteoporosis among HIV-infected adults was 52-67% and 
15%, respectively [81,82]. A study conducted in a large United States reported higher 
prevalence of overall fracture in the HIV-infected group compared with uninfected 
controls (2.87 vs. 1.77 patients with fractures per 100 persons) [8]. Furthermore, the HIV 
Outpatient Study revealed that the adjusted fracture rate among HIV-infected adults 
increased from 57.7 to 89.9 per 10000 population between the years 2000 and 2008, 
respectively and that it was 49.6-72.9% higher than in uninfected population over the 
study period [9]. However, an increased risk of fracture events among HIV-infected 
children and adolescent has not been documented. A prospective cohort 
PACTG219/219C study, which followed more than 1000 HIV-infected children for a 
median of 5 years showed similar incidence rate of fracture among HIV-infected 
compared with HIV-exposed but uninfected children (1.2 vs. 1.1 per 1000 person-years) 
[83]. Since fracture is a long-term complication of adverse bone health, these populations 







Measurements to assess bone health in HIV-infected children and adolescents  
Standard measurement in clinical practice 
DXA is a non-invasive imaging technique that uses two X-ray beams with 
different photon energy levels aimed at the bone to be measured. The BMD can be 
determined from the absorption of each beam by bone once soft tissue absorption is 
subtracted. DXA is the most commonly used bone densitometric technique for children 
and adolescents throughout the world [10]. The measurements provided include bone 
mineral content (BMC, grams) and areal bone mineral density (BMD, g/cm2). The most 
appropriate skeletal sites for performing densitometry in children and adolescents are 
posterior-anterior (PA) lumbar spine and total body less head [10]. Compared with 
conventional radiographs, measurement of the spine provides more information about the 
trabecular bone status, while total body measurement focuses more on cortical bone 
status [84]. In children with short stature or delayed growth, the areal BMD and BMC 
should be adjusted in order to eliminate the influences of bone size and skeletal 
dimension. For total body less head, adjustment should be performed using the height Z-
score. For the spine, adjustment can be made by using either bone mineral apparent 
density (BMAD) or the height Z-score [10]. According to the 2013 International Society 
for Clinical Densitometry (ISCD) Pediatric Official Positions, an areal BMD Z-score less 
than or equal to -2.0 SD is described as low bone mass or BMD [10,85].  
 
Advanced measurements in research settings 
During the past decade, the concept of bone strength has encompassed a number 




mineralisation and cellularity, aspects of called bone quality [86-88]. Summary of 
advanced techniques for assessing bone health are shown in Table 1.  
Bone histomorphometry is a histological examination of bone biopsy specimens to 
obtain qualitative and quantitative information on in vivo bone structure and remodelling. 
It is the gold standard for bone metabolic and mineralisation evaluation [89,90]. 
Currently, there are non-invasive imaging techniques using three-dimensional 
reconstruction for bone microstructure and microarchitecture analysis [91]; therefore 
bone biopsy is frequently avoided.  
Quantitative ultrasonography (QUS) is a non-invasive method using high 
frequency sound waves that are transmitted through bone to assess the bone quality and 
strength. The longitudinal sound wave transmitted through calcaneus is the accepted 
measurement to determine bone health status [92].  
Quantitative computerized tomography (QCT) is a three-dimensional imaging 
technique to assess true volumetric density (mg/cm3) without the overlapping of other 
tissues [93]. This technique ranges from a volumetric QCT to advanced imaging 
modalities such as high-resolution CT (hrCT) and microCT. Currently, there is no 
preferred QCT method for clinical evaluation in children and adolescents [94]. Most 
QCT studies in children investigated peripheral sites, primarily the radius and tibia, 
because of radiation exposure concerns [94]. The advantage of QCT over DXA is that it 
provides a separate analysis of trabecular or cortical components of bone.  
Quantitative magnetic resonance imaging (QMRI) is a non-invasive, non-ionising 
radiation technique that provides three-dimensional imaging of trabecular bone 




and a series of radiofrequency waves to generate three-dimensional images of the 
hydrogen protons in the water within skeletal tissues [88].  
Biochemical markers of bone turnover are helpful research tools to reflect the 
ongoing bone remodelling processes. Currently available markers are classified into 
biochemical markers of bone formation and resorption [95-98]. Biomarkers of bone 
formation are products of active osteoblasts expressed during different developmental 
stages, including: (i) osteoblast-specific enzymes such as bone-specific alkaline 
phosphatase (BALP); (ii) osteoblast-related protein such as OC; and (iii) by-products of 
collagen synthesis such as PINP. All can be measured in serum or plasma [95-98]. The 
biomarkers for bone resorption are classified into: (i) osteoclast-specific enzymes such as 
tartrate-resistant acid phosphatase (TRACP) 5b; and (ii) collagen degradation products 
such as hydroxyproline, pyridinoline, deoxypyridinoline, CTX, and N-terminal cross-
linked telopeptide of type I collagen (NTX) [95-98]. The measurements can be performed 













Bone health assessment in HIV-infected children and adolescents in clinical practice 
 The recommendations for the evaluation and management of bone disease in 
HIV-infected adults have recently been developed by HIV specialists from 16 countries 
[103]. The screening for adverse bone health depends on an individual’s risk for fragility 
fracture. For individuals with major risk factors, including a previous history of fragility 
fracture; receipt of glucocorticoid treatment for more than 3 months; and at high risk for 
falls, BMD assessed by DXA should be performed. Additionally, DXA, if available, is 
recommended for all men age >50 years, postmenopausal women and individuals with a 
10-year risk of major osteoporotic fracture >10% by the Fracture Risk Assessment Tool 
(FRAX) score. For those without major risk factors, including men age 40-49 years and 
premenopausal women age >40 years, FRAX (without DXA) is the recommended 
assessment [103]. FRAX is a prediction tool for assessing an individual’s fracture risk 
and is applicable for people aged between 40 and 90 years. The model incorporates 
several components such as age, race, sex, body mass index, smoking, alcohol 
consumption, long-term use of glucocorticoids, vitamin D deficiency, prior fragility 
fracture and parenteral history of hip fracture into the calculation [103]. Therapeutic 
management guidelines vary by country and are based on the availability, as well as cost 
of diagnostic tools and medications. In the United States, anti-osteoporosis treatments are 
prescribed in individuals presenting with hip or vertebral fracture, osteoporosis (T-score 
no more than -2.5), or osteopenia (T-score between -1.0 and -2.5) with a 10-year 
probability of hip fracture >3% or major osteoporosis-related fracture ≥20% based on 
FRAX [104]. The follow-up interval of DXA should be adjusted according to degree of 




score between -2.0 and -2.5) and after 5 years for those with mild to moderate osteopenia 
(T-score between -1 and -2) [103]. 
The objective of bone health assessment in the paediatric population is to screen 
children who fail to achieve the expected gains in bone size, mass and strength, which 
leaves them vulnerable to fracture as they age. The ISCD 2013 Statement recommends 
that DXA should be considered only in children and adolescents who may benefit from 
interventions and those whose DXA results will influence management [105]. Among 
chronic diseases, cystic fibrosis has a well-established recommendation for bone health 
assessment and monitoring. The European Cystic Fibrosis Mineralisation Guidelines 
recommend the first routine bone density scans at age around 8-10 years, to be repeated 
every 5 years if the BMD Z-score is above -1; every 2 years if the Z-score is between -1 
and -2; and every year if the Z-score is below -2 [106]. However, to date, there is no 
specific recommendation for DXA screening among HIV-infected children and 
adolescents in any national or international guidelines. In settings where DXA is 
available and accessible, bone density scans may be performed at 6-12 months after ART 
initiation since transient reduction in bone mass may be occurring, with repeat 
measurements every year if BMD Z-score is less than or equal -2. In settings where 
access to DXA is limited, one may consider performing bone density scans only in 
individuals who have a combination of multiple risk factors for bone demineralisation, 
for example history of wasting or stunting, advanced HIV disease, use of TDF with 





Management of adverse bone health in perinatally HIV-infected children and 
adolescents 
As adverse bone health during childhood and adolescence may result in adult 
osteoporosis and bone fragility, several approaches, primarily prevent bone loss and 
optimise bone health, should be implemented during these critical periods.  
 
General management    
Promoting a healthy lifestyle 
 Healthy lifestyle choices include avoiding smoking and heavy alcohol 
consumption. Smoking is a major lifestyle risk factor for osteoporosis. Studies in twins 
have provided a powerful study design by controlling for age, sex, genetic background to 
identify the effects of smoking on bone health [107-109]. A cross-sectional study of 41 
pairs of female twins found that smoking one pack of cigarettes per day throughout 
adulthood would reduce BMD by approximately 5–10%, thus increasing the risk for 
osteoporosis by the time of menopause [107]. Similarly, a study of 146 female twin pairs 
showed that a discordance of 10 pack-years smoking was related to a 2.3–3.3% decrease 
in BMD at the lumbar spine, proximal femur and total body [108]. Furthermore, meta-
analyses indicated that smoking substantially increased hip fracture by 31–60% when 
comparing current smokers with non-smokers [110-112].  
 Alcohol consumption negatively impacts bone health in several ways. First, 
excessive alcohol consumption causes hypovitaminosis D, which in turn reduces calcium 




production, a male hormone linked to the production of osteoblasts [115], while, cortisol, 
a hormone that arrests osteoblast differentiation, is increased [116].  
 
Exercise 
 Weight-bearing and muscle strengthening exercises are important for building and 
maintaining bone density. Weight-bearing exercise can be either high impact, such as 
dancing, running, jumping, gymnastics, soccer, basketball or low impact, such as fast 
walking or low-impact aerobics. Muscle strengthening exercises include weight lifting, 
using elastic exercise bands or weight machine, or functional movements. Previous 
studies showed that children who usually participate in high-impact activities have higher 
bone mass compared with individuals who are less active or frequently engage in non-
weight bearing exercises [117-120]. The American College of Sports Medicine 
recommends exercising for 10-20 minutes per day, at least 3 days per week [117]. These 
exercise prescriptions could improve bone strength in children and adolescents.      
 
Nutrition 
 Key bone nutrition includes calcium and vitamin D [121]. The Institute of 
Medicine (IOM) recommendation for daily calcium intake for children and adolescents 
age 9-18 years is 1300 mg per day [122]. In clinical practice, diet should be the primary 
source for calcium. Calcium supplementation should be provided to individuals who 
unable to obtain adequate calcium from their diet and who are at high risk for adverse 
bone health. Common dietary sources of calcium are dairy products, soymilk, soybeans, 




for children and adolescents age 9-25 years is 600 IU per day [122]. The most common 
source of vitamin D is sunlight. However, in countries without year-round sunlight, foods 
containing vitamin D such as fatty fish (e.g., salmon, tuna and mackerel) and fish oils are 
among the best sources. Vitamin D-fortified foods may be available in resource-rich 
countries [123], but they are not available in resource-limited settings.  
 A high prevalence of vitamin D deficiency and insufficiency among HIV-infected 
children and adolescents has been reported, ranging from 71% to 96% [124-127]. 
Vitamin D deficiency may diminish calcium absorption in the gastrointestinal tract. 
Therefore, if 25-hydroxyvitamin D (25-OHD), a surrogate for vitamin D levels, is lower 
than 30 ng/ml, supplementation should be initiated. However, in settings where 25-OHD 
measurement is not available, supplementation should be considered based on history of 
vitamin D intake and clinician decision. However, evidence demonstrating the benefit of 
calcium and vitamin D supplementation on bone health among HIV-infected children and 
adolescents is limited and controversial [128,129]. A randomised clinical trial assessing 
the effects of calcium (1 g per day) and vitamin D3 (1600 IU per day) supplementation 
for 2 years on bone mineral accrual among HIV-infected children and adolescents with 
normal baseline BMD in the United States found no significant difference in BMD when 
compared with placebo groups [128]. In contrast, a recent small observational study 
supplementing 1200 mg calcium and 400 IU vitamin D3 daily for 6 months showed a 
significant improvement of lumbar spine BMD and BMD Z-scores among HIV-infected 
Thai adolescents with low BMD at baseline [129]. Currently, there are on-going 
randomised clinical trials determining the impact of calcium and/or vitamin D 




Pharmacological interventions  
 There are several agents used in the treatment of low BMD in HIV-infected 
populations, including anti-resorptive therapies (bisphosphanates, serum oestrogen 
receptor modulators or SERMs, and monoclonal antibody to RANKL), strontium ranelate 
and peptides of the parathyroid hormone family [130]. Among all treatment options, 
bisphosphonates are the longest established therapy of osteoporosis. Bisphosphonates are 
derivatives of inorganic pyrophosphate that have a high affinity for bone minerals. These 
agents are preferentially incorporated into sites of active bone remodelling and 
accelerated bone turnover and inhibit hydroxyapatite breakdown, which in turn 
suppresses bone resorption [131]. This property results in their utility as clinical agents 
for osteoporosis treatment. Alendronate and zolendronate are the only two agents 
recommended for HIV-infected adults with osteoporosis [103]. However, clinical 
evidence for efficacy of these medications in HIV-infected individuals is scarce and no 
studies in children and adolescents have taken place. Previous randomised clinical trials 
of the bisphophonates, alendronate (weekly) or zolendronate (annually), in HIV-infected 
adults with low bone density demonstrated significant improvement of BMD compared 
to placebo groups [132-137]. Before bisphosphonates can be recommended as an anti-
osteoporosis treatment, larger studies with longer follow up periods should be performed. 
Currently, there are several ongoing randomised clinical trials that aim to determine the 
efficacy of alendronate on bone density among HIV-infected adolescents and young 





 Adverse bone health is common in perinatally HIV-infected children and 
adolescents, particularly those living in middle-income countries. The pathogenesis of 
low BMD is complex, and is related to HIV disease course and systemic inflammation 
(immunoskeletal interface). Many factors, both traditional and HIV specific, can lead to 
adverse bone health. An important consequence of low bone density during childhood 
and adolescence is compromised PBM, which may result in osteoporosis and bone 
fracture later in life. Refraining from smoking and heavy alcohol consumption, 
performing regular weight-bearing exercises and adequate dietary intake of calcium are 
basic health education messages for patients to optimise bone health. More data are 
required to support the efficacy of calcium and vitamin D supplementation, and 
bisphosphonates in restoring bone mineralisation and preventing bone loss among HIV-
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Advantages Disadvantages Clinical data from HIV-infected children and 
adolescents 




 Widely available  
 Safe 
 Excellent precision 
 High reproducibility 
 Examination time 5 minutes 
 Subject to systematic errors  
 Cannot differentiate cortical 
and trabecular bones 
 Limited paediatric normative 
data references 
 HIV-infected adolescents had high prevalence of 
BMD Z-score <-2 (16-32%) in middle-income 
countries  [13-16] 
 BMD and BMC of HIV-infected adolescents is 
significantly lower than healthy controls [12,14] 




 Radiation free 
 Portable and simple to 
operate  
 Correlates well with DXA 
 Cost-effective 
 Limited skeletal site of 
measurement 
 Lack of paediatric normative 
data for interpretation  
 HIV-infected children with severe clinical symptoms 
had lower calcaneal BUA Z-score [63] and 
phalangeal SOS [99] compared with healthy controls 
 Tibial and radial SOS were associated with lumbar 
spine BMC and BMD, and total body BMC and 
BMD [100] 





 More accurate assessment 
of BMD than DXA 
 Provide separate analysis of 
cortical and trabecular 
bones 
 Not susceptible to 
degenerative changes of 
bone calcifications  
 High radiation dose 
 High cost 
 Hard to access 
 Lack of paediatric normative 
data for interpretation 
 Similar vertebral volumetric bone density in HIV-
infected children compared with controls [101] 
 DXA Z-scores were significantly lower than QCT Z-
scores in HIV-infected children [101] 
 Cortical BMD (peripheral QCT) was positively 
associated with NNRTI use, but negatively 





 Lack of ionising radiation 
 Ability to investigate 
marrow fat content, marrow 
diffusion and marrow 
perfusion 
 Long acquisition time 
 Requires specialised machine 
 High cost 










Advantages Disadvantages Clinical data from HIV-infected children and 
adolescents 




 Can be performed from 
blood and urine specimens 
 Helpful tools in diagnosis 
and treatment assessment of 
bone health and diseases  
 Diurnal variation 
 Limited paediatric normative 
data and cut-off levels 
 
 Higher serum BALP and urine NTX in ART-
experienced HIV-infected children compared with 
untreated children and healthy controls [102] 
 Significantly reduced osteocalcin and urinary 
deoxypyridinoline in HIV-infected children with 
severe clinical symptoms compared with healthy 
controls [63] 
 CTX and PINP levels were not different between 
HIV-infected adolescents with and without low 
BMD, but PINP was significantly inversely 
correlated with BMD Z-score [13] 
 
Abbreviations: BALP: bone-specific alkaline phosphatase; CTX: C-terminal cross-linked telopeptide of type I collagen; NNRTI: non-nucleoside 
















Table 2. Ongoing randomised clinical trials on the interventions for improve bone health among HIV-infected adolescents and 






Study population Intervention  Primary outcome 






Age 11-24 years  
Lumbar spine BMD Z-
score <-1.5 or history of 
fragility fracture 
ARM 1: Oral alendronate 70 mg weekly for 96 
weeks  
 
ARM 2: Oral alendronate 70 mg weekly for 48 
weeks plus placebo for 48 weeks 
 
ARM 3: Placebo for 96 weeks 
 
Changes of LS BMD 




Havens P et al. 
ATN109 
(NCT01751646) 
United States  
Puerto Rico 
Age 16-24 years receiving 
TDF-containing ART  
ARM 1: Vitamin D3 50000 IU orally every 4 
weeks for 48 weeks 
ARM 2: Placebo for 48 weeks 
 
Changes in LS BMD 
after 48 weeks of 
supplementation   




Thailand Adolescents age 10-20 
years receiving stable  ART 
ARM 1: Co-formulated oral calcium (600 mg 
elemental calcium)/vitamin D3 (200 IU) twice 
daily for 48 weeks 
ARM 2: Co-formulated oral calcium/vitamin D3 
twice daily plus vitamin D2 (20000 IU/cap) once 
weekly for 48 weeks 
 
Changes in LS BMD 




Tan D et al. 
BATARI  
(NCT01968850) 
Canada ART-naïve age >18 years 
with low fracture risk 
(FRAX 10-year fracture 
risk scores <10%) 
ARM 1: Standard of care 
ARM 2: Co-formulated oral alendronate (70 
mg)/vitamin D3 (5600 IU) weekly started at time 
of ART initiation for 24 weeks 
ARM 3: Co-formulated oral alendronate (70 
mg)/vitamin D3 (5600 IU) weekly started at 
week 24-48 of ART  
Changes in LS and 
proximal femur BMD 




Table 2. Ongoing randomised clinical trials on the interventions for improve bone health among HIV-infected adolescents and 






Study population Intervention  Primary outcome 
Mallon PW et al. 
APART 
(NCT02322099) 
Ireland ART-naïve adults age >30 
years initiated with 
TDF/FTC 
ARM 1: Oral alendronate (70 mg) weekly plus 
daily calcium (500 mg elemental 
calcium)/vitamin D3 (400 IU) for 14 weeks 
ARM 2: Placebo plus calcium (500 mg 




differences in the 
change in total hip, 
LS, femoral neck 
BMD and body 
composition to week 
50 
 
Abbreviations: ART: antiretroviral therapy; BMD: bone mineral density; FRAX: fracture risk assessment tool; FTC: emtricitabine; LS: lumbar 




Figure 1. The prevalence of low bone mineral density among perinatally HIV-




Note: Low bone mineral density (BMD) is defined as BMD Z-score <-2.  
The BMD measurements shown are taken at lumbar spine, except where otherwise indicated. 
 






Figure 2. The immunopathogenesis and risk factors of low BMD among HIV-
infected children and adolescents. 
 
Note: Green textboxes with solid border represent important risk factors of low BMD. Purple 
textboxes with dashed border represent components of the immune system. Yellow textboxes 
with dashed and dotted border represent components of the skeletal system. A blue textbox with 
dotted border represents the immunoskeletal interface. 
 
Abbreviations: ART: antiretroviral treatment; BALP: bone-specific alkaline phosphatase; BMD: 
bone mineral density; CTX: C-terminal cross-linked telopeptide of type I collagen; IL-6: 
interleukin-6; NTX: N-terminal cross-linked telopeptide of type I collagen; OC: osteocalcin; 
PICP: procollagen type I carboxy-terminal propeptide; PINP: procollagen type I amino-terminal 
propeptide; RANKL: receptor activator of nuclear factor κβ ligand; SOFAT: secreted 
osteoclastogenic factor of activated T-cells; TNF-alpha: tumor necrotic factor-alpha; TRACP 5b: 
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Objectives: This study aimed to determine the prevalence of low bone mass and assess 
its relationship with abnormal bone turnover among HIV-infected Asian adolescents. 
Methods: A multicenter, cross-sectional study was conducted at 4 pediatric HIV centers 
in Thailand and Indonesia. Perinatally HIV-infected adolescents aged 10-18 years 
receiving antiretroviral therapy (ART) with virologic suppression (HIV RNA <400 
copies/ml) were enrolled. Study assessments included lumbar spine (L2-L4) dual-energy 
X-ray absorptiometry, serum 25-hydroxyvitamin D, bone turnover markers and pro-
inflammatory cytokines. Bone mineral density (BMD) and bone mineral apparent density 
(BMAD) Z-scores were calculated based on Thai normative age- and sex-matched 
references. Low bone mass was defined as BMD or BMAD Z-scores <-2.  
Results: Of 396 participants, 57% were female. The median age [interquartile range 
(IQR)] was 15.0 (13.3-16.9) years, and 73% were in Tanner stage 3-5. At enrollment, 
median CD4+ (IQR) was 734 (581-907) cells/mm3, and 37% were on protease inhibitor 
(PI)-based regimens. Overall prevalence of lumbar spine BMD and BMAD Z-scores <-2 
were 16.4% and 8.3%, respectively. Z-scores were lower with older age, female sex, 
body mass index (BMI) <5th percentile, PI exposure and CD4+ <15% before ART 
initiation. Increased bone turnover markers were inversely associated with BMD and 
BMAD Z-scores. Pro-inflammatory cytokines tended to have a positive but not 
significant association with bone turnover markers. 
Conclusion: Low bone mass was linked to advanced age, female sex, low BMI and PI 




Dysregulation of bone turnover was associated with bone demineralization, while chronic 

























Significant success in expanding access to effective antiretroviral therapy (ART) 
has turned HIV infection into a chronic life-long illness. Perinatally infected infants and 
children now survive into adolescence and young adulthood similar to their healthy peers 
[1]. However, long-term, non-AIDS-related complications associated with HIV infection 
and ART have been emerging [1-3]. Adverse bone health is a specific concern in this 
population undergoing normal physical development [3-5]. Low bone mass, evaluated by 
dual-energy X-ray absorptiometry (DXA), has been reported in HIV-infected children 
and adolescents [6-10]. The prevalence of low bone mass, which is defined as bone 
mineral density (BMD) Z-score <-2.0, has been observed to be higher in middle-income 
(17-32%) [6-8] compared with high-income countries (4-8%) [9,10]. Importantly, bone 
mass in this population has appeared to be much lower than their age- and sex-matched 
HIV-exposed but uninfected [9], and healthy controls [11-13].  
There are multiple factors associated with decreased bone mass in HIV-infected 
individuals [6-20]. Hypovitaminosis D, inadequate calcium intake, limited physical 
activity, cigarette smoking, corticosteroid use, malnutrition, low lean body mass, short 
stature and delayed puberty are among the important traditional risk factors [7,9-12]. In 
addition, HIV-specific factors, including HIV itself, advanced HIV disease, impaired 
immunologic and virologic status, specific antiretroviral drugs, as well as chronic 
immune activation and inflammation due to HIV infection are the major determinants 





Because bone is a dynamic tissue, it continuously undergoes remodeling, which 
consists of bone resorption (mediated by osteoclasts) and formation (mediated by 
osteoblasts) throughout life to maintain its strength and mineral homeostasis [21,22]. 
Uncoupling between these two processes can result in increased bone turnover, a net 
decline in bone mass, and the development of bone disorders [22].   
Since a great deal of bone mineral accrual occurs during childhood and 
adolescence and approximately 90% of final adult bone mass is attained by 18 years of 
age [23], the impairment of bone mineralization during these critical periods can 
contribute to serious consequences, particularly osteoporosis and bone fracture, later in 
life [24,25]. However, information on the extent of bone demineralization and its 
pathogenesis are limited in resource-constrained settings, where factors affecting bone 
may be different, for example, race and ethnicity, seasonality, lifestyles, foods and 
dietary supplements. This study aimed to determine the prevalence and important 
associated factors of low bone mass, as well as its relationship with abnormal bone 












Methods and measurements 
Study design and participants  
This multicenter, cross-sectional study was conducted in four clinical research 
sites in Asia: 3 in Thailand [HIV Netherland Australia Thailand (HIV-NAT), Bangkok; 
the Faculty of Medicine and Research Institute for Health Sciences (RIHES), Chiang 
Mai; Srinagarind Hospital, Khon Kaen University (KKU), Khon Kaen], and one in 
Indonesia [Cipto Mangunkusumo General Hospital (CMGH), Jakarta]. Eligible 
participants were perinatally HIV-infected adolescents aged 10 to 18 years who were on 
ART and had a documented history of virologic suppression (plasma HIV-1 RNA <400 
copies/ml) within the past 6 months. Participants were excluded if they had underlying 
bone disease or established risks factors for adverse bone health, such as renal failure or 
endocrine diseases, or received medications for treatment bone demineralization or other 
medications that affect bone health (e.g., corticosteroids). The study was approved by the 
institutional review boards at all research sites. All participants and their caregivers 
provided written informed consent and assent, as appropriate, before taking part enrolling 
in this study. 
 
Data collection and clinical assessments 
Clinical data collection of HIV-specific characteristics, including World Health 
Organization (WHO) clinical stage, CD4+ T-cell percentage, plasma HIV-1 RNA, ART 
history and duration of treatment were abstracted from medical records. Physical 




Physical activity levels, sun exposure duration and daily dietary intake were obtained by 
interview using standard questionnaires in Thai and Bahasa. 
Weight and height measurements were converted into age- and sex-standardized 
Z-scores, using a Thai normative reference [26]. Body mass index (BMI) was calculated 
[weight (kg) / height (m2)] and transformed into BMI percentile based on the US Centers 
for Disease Control and Prevention (CDC) reference [27]. Physical activity levels were 
assessed and reported in the form of physical activity scores (PAQ), ranging from 1 (low) 
to 5 (high) [28]. The average duration of sun exposure was calculated and described as 
hours per day. Daily calories (kcal/day) and calcium (mg/day) intake were analyzed using 
the Institute of Nutrition, Mahidol University Calculation (INMUCAL)-Nutrients 
Program, version 3.0 (Institute of Nutrition, Mahidol University) [29].    
 
Blood sample collection and laboratory analysis 
At enrollment, blood samples for calcium, phosphate, 25-hydroxyvitamin D (25-
OHD), intact parathyroid hormone (iPTH), bone turnover markers and pro-inflammatory 
cytokines were collected. All participants were asked to fast overnight for at least 12 
hours before blood sampling. Phlebotomy was performed by trained nurses in the 
morning between 8:00 to 10:00 a.m. to avoid diurnal variation in bone turnover markers. 
Blood tubes were centrifuged for 10 minutes (1200 x g at room temperature) to obtained 
serum, which was stored at -70°C until laboratory analysis. 
The 25-OHD, iPTH, and bone turnover markers which included C-terminal cross-
linked telopeptide of type I collagen (CTX; bone resorption marker) and procollagen type 




automated electrochemiluminescence immunoassay (ECLIA) (Roche Diagnostics, 
Mannheim, Germany) on Cobas® e411 immunoassay analyzer (Roche Diagnostics, 
Mannheim, Germany). Pro-inflammatory cytokines, including interleukin (IL)-1, IL-1β, 
IL-6 and tumor necrotic factor (TNF)- were quantified using sandwich enzyme-linked 
immunosorbant assay (ELISA) with DuoSet® ELISA development system (R&D 
Systems, Minneapolis, Minnesota, USA) on microplate reader (Varioskan Flash, version 
4.00.53). The standard curves were performed in duplicate and generate reproducible 
optical density. Laboratory procedures were performed according to the manufacturer’s 
instructions. Blood specimens for each lab were analyzed by a single technician at a 
single reference site at RIHES, Chiang Mai University (Chiang Mai, Thailand) for 25-
OHD, iPTH, and bone turnover markers; and the HIV-NAT, Thai Red Cross AIDS 
Research Centre (Bangkok, Thailand) for pro-inflammatory cytokines. The other 
laboratory measurements were conducted locally using routine laboratory analyses. The 
normal level of 25-OHD was 30 ng/ml or above [30], and the lower and upper limit of 
normal for iPTH were 10 and 65 pg/ml [31]. The normal range of calcium was 8.4-10.2 
mg/dl, and phosphorus ranges were 3.3-5.4 mg/dl (age 10-15 years) and 2.4-4.4 mg/dl 
(age >15 years). The normal range for alkaline phosphatase levels were 100-390 U/l 
(male) and 100-320 U/l (female), respectively. 
 
Bone health evaluations 
Lumbar spine (L2-L4) bone mass was evaluated by DXA technique using 
scanners from the same manufacturer (Lunar, General Electric [GE] Healthcare, 




radiologic technologists according to standard methods. The machines were calibrated on 
a daily basis following the standard quality assurance procedures provided by the 
manufacturer. Additionally, a spine quality control phantom was scanned weekly 
according to the manufacturer recommendations to monitor the performance of a scanner 
over time. The scans were analyzed using enCORE software version 14.1 (enCORE, GE 
Healthcare, Madison, Wisconsin, USA). 
Lumbar spine bone mass measurements for all participants were reported as BMD 
Z-scores, which standardizes the absolute BMD results against the average results 
expected for a Thai adolescent of similar age and sex [32]. Additionally, bone mineral 
apparent density (BMAD) was calculated by using the formula BMAD (g/cm3) = BMD 
(g/cm2) × (4 / [¶ × width of lumbar spine measurement area]) in order to eliminate the 
effects of height and skeletal size on bone mass measurement. BMAD Z-score was also 
computed based on a Thai normative reference [32]. This normal reference for BMD and 
BMAD was conducted in 381 healthy Thai children and adolescents aged between 5-18 
years who resided in urban areas in Bangkok. There were 114 male and 127 female 
adolescents (about 10-15 adolescents per each 1-year age category) aged between 10-18 
years whom were used as age- and sex-matched controls for our participants [32]. 
According to the 2013 Pediatric Official Positions of International Society for Clinical 
Densitometry (ISCD), lumbar spine BMD and BMAD Z-scores <-2 were described as 







Sample size and power 
  In previous studies conducted in middle-income countries, the prevalence of low 
bone mass (BMD Z-score <-2) among perinatally HIV-infected adolescents varied from 
23.8-32.4% [7,8]. We had hypothesized that the prevalence among our adolescents would 
be 30%. Therefore, in order to have a study that contained 80% power with 2-sided 
significance level of 0.05, we needed to enroll approximately 390 adolescents.  
 
Statistical analysis 
Characteristics and laboratory results of adolescents with BMD Z-score <-2 and 
>-2 were compared using chi-square and Wilcoxon rank sum tests for categorical and 
continuous variables, respectively. Bone mass, including BMD and BMAD, of HIV-
infected individuals were compared with matched healthy peers by age (1-year class 
interval) and sex (male vs. female) categories, using the Student t test. Univariate linear 
regression analyses were performed to identify factors associated with BMD and BMAD 
Z-scores. Covariates were retained in a multivariable model if they were associated with 
a P <0.1 in univariate analysis. Variables suspected to be potential effect modifiers of the 
associations were assessed. The magnitudes of association were summarized with mean 
difference and adjusted mean difference, together with their 95% confidence intervals 
(CI), in univariate and multivariable analyses, respectively.  
In the models determining the association between bone turnover and bone mass, 
bone biochemical markers (CTX and PINP) were adjusted by significant factors in 
multivariable analysis. Each marker was transformed into their natural logarithms in 




log-transformed variables were back-transformed and then interpreted on the original 
scale. The magnitudes of association were reported as mean differences and adjusted 
mean differences per 10% increase in bone biomarker levels. To assess the association of 
chronic immune activation and inflammation and bone turnover, multivariable analyses 
were performed. Pro-inflammatory cytokines (IL-1, IL-1β, IL-6 and TNF-) and bone 
biochemical markers were transformed into their natural logarithms during analysis, and 
were back-transformed into the original scale for interpretation. The magnitudes of 
association were reported as percentage change in geometric mean of each bone 
biomarker per 10% increase in each cytokine.  
A two-sided P <0.05 was considered to indicate statistical significance. All 
statistical analyses were performed using Stata statistical software, version 13. (StataCorp 

















Between April and December 2014, 396 perinatally HIV-infected adolescents 
were enrolled, of whom approximately half (57%) were female. The median age was 15.0 
years, and 73% were in Tanner Stage 3-5. Prior to ART initiation, 167 adolescents 
(43.7%) were in WHO clinical stage 3-4, with median CD4+ T-cell percentage of 12.8. At 
enrollment, two-thirds were taking non-nucleoside reverse transcriptase inhibitor-based 
treatment, and one-third, protease inhibitor (PI)-based treatment, with a median duration 
of ART use of 9.3 years and median CD4+ T-cell count of 734 cells/mm3. All had HIV 
RNA <400 copies/ml and 96% had HIV RNA <50 copies/ml. Among adolescents with 
available data, the median PAQ scores was 1.8 out of 5 (n = 363), and sun exposure 
duration was 0.4 hours per day (n = 246) (Table 1). 
 
Laboratory results and bone turnover markers 
The median serum 25-OHD level was 26.3 ng/ml, and iPTH level was 41.7 pg/ml. 
The median serum calcium level was 9.5 mg/dl. For bone turnover markers, the median 
CTX and PINP levels were 1270 ng/L and 337 μ/l, respectively. The other laboratory 
results related to bone metabolism are shown in Table 2. 
 
Lumbar spine bone mass of HIV-infected adolescents 
Of 396 adolescents, 65 had lumbar spine BMD Z-scores <-2, representing a 
prevalence of low bone mass of 16.4% (95% CI: 12.7-20.0%). Thirty-three adolescents 




5.6-11.1%). The mean BMD (standard deviation) of HIV-infected adolescents was 0.899 
(0.170) g/cm2, which was significantly lower than that of age- and sex-matched HIV-
uninfected controls [0.943 (0.166) g/cm2, P = 0.001]. The mean BMAD for those with 
HIV was less than that of healthy controls, but the difference was not statistically 
significant (0.319 vs. 0.322 g/cm3; P = 0.48). The comparison of lumbar spine bone mass 
between HIV-infected and healthy adolescents stratified by sex is demonstrated in Figure 
1. 
 
Associated factors of low bone mass  
In the multivariable analysis for BMD, older age, BMI <5th percentile, boosted PI 
exposure and CD4+ T-cell <15% prior to ART initiation were significantly associated 
with lower BMD Z-scores (Table 3). In the multivariable analysis for BMAD, in addition 
to the above, female sex was also an independent factor for lower BMAD Z-score (Table 
3). Daily calcium intake was not significantly associated with BMD or BMAD Z-scores 
(P >0.05). 
 
Association between bone turnover and bone mass  
In the multivariable analysis for BMD, PINP was inversely associated with BMD 
Z-score, while CTX showed a trend of negative association that did not reach statistical 
significance. In the multivariable analysis for BMAD, PINP and CTX were negatively 






Associations of chronic immune activation and inflammation with bone turnover 
In univariate analysis, IL-1 and IL-1β demonstrated a significant positive 
association with CTX (P = 0.02 and 0.04, respectively), while IL-6 and TNF- showed a 
trend of positive association that did not reach statistical significance. After controlling 
for confounders (age, sex, TDF exposure, duration of ART and iPTH level), IL-1 and 
IL-1β were no longer significantly associated with CTX (Supplemental Table 2). 
In the univariate but not the multivariable analysis, there was a trend towards a 




















 Sixteen percent of our perinatally HIV-infected Asian adolescents had evidence of 
adverse bone health defined as having lumbar spine BMD Z-scores <-2. Bone mass for 
these individuals were much lower than that of their age- and sex-matched healthy peers. 
Older age, female sex, low BMI, boosted PI exposure, and low CD4+ prior to ART 
initiation were associated with decreased bone mass. The dysregulation of bone turnover, 
demonstrated by increased bone formation and resorption markers, correlated with low 
bone mass. In addition, there was a trend towards a positive association between levels of 
pro-inflammatory cytokines and bone turnover markers. 
 The 16.4% prevalence of low bone mass (lumbar spine BMD Z-score <-2) among 
our Asian adolescents was comparable to that observed in middle-income countries (17-
32% in Brazil) [6,8], but much higher than those documented in resource-rich countries 
(4% in United States and 8% in the Netherlands) [9,10]. This may be because the age, 
anthropometric parameters and HIV disease status are more similar in our and the 
Brazilian participants [6,8], but not the US and Dutch participants who were younger, had 
better nutritional status and less severe HIV disease [9,10]. These key demographic, 
growth and HIV disease parameters likely contributed to differences in prevalence of low 
bone mass in resource-rich vs. limited settings. 
 As recommended by the ISCD, BMD results for children and adolescents can be 
affected by chronic diseases, including HIV/AIDS, which lead to short stature or delayed 
sexual maturation. Therefore, BMAD may be a preferred endpoint in those infected by 
HIV, as it is adjusted for height, bone size and skeletal dimension [33]. In this study, we 




and found that the prevalence of low bone mass (lumbar spine BMAD Z-score <-2) 
declined to 8.3%. Since about one-fourth of our adolescents were short-for-age [height-
for-age Z-score (HAZ) <-1.5], using BMAD Z-score to determine the prevalence of low 
bone mass might be more appropriate than using BMD Z-score, and this made our 
prevalence comparable to those documented in resource-rich countries. Additionally, the 
ISCD recommends employing HAZ adjustment to remove the confounding effect of 
height on bone density measurement [33]. This rationale has been supported by Zemel et 
al, who found that the HAZ adjustment is the least biased method compared with other 
approaches [34]. Unfortunately, this study could not assess the HAZ-adjusted BMD Z-
score because there are no normative Asian reference data. Moreover, the publicly 
available web-based analysis tool is developed for US children based on BMD measured 
using the Hologic DXA system that is different to ours. 
In this study, we found that HIV-specific factors, including boosted PI exposure 
and low CD4+ prior to ART initiation, and traditional risk factors, including older age, 
female sex and low BMI (a combination of weight and height) were associated with 
lower bone mass. PI regimens and poor immunological status have been reported as 
important predictors for adverse bone health [9,10,13,34,35]. In addition, several studies 
reported that delayed linear growth and poor weight gain were independently associated 
with compromised bone mass in HIV-infected adolescents [7-9,12]. We used Thai 
normative reference to calculated height-for-age and weight-for-age Z-scores for all 
participants in this study, but since anthropometric parameters for Thai and Indonesian 
adolescents were comparable, this would not impact our results [26,36]. Because there 




percentile might have inflated the number of adolescents who had low BMI (BMI <5th 
percentile) and magnified its association with decreased bone mass. We showed no 
association between daily calcium intake and bone density, which was similar to a 
previous study conducted in HIV-infected adults living in Italy where calcium-rich foods 
are commonly available [37]. Unfortunately, the missing data on sun exposure and 
physical activity prohibited accurate assessment of their relationships with poor bone 
mass in our study. 
Disturbance of bone turnover process can lead to a net reduction in bone mass 
[38]. In this study, we observed that the high bone turnover, reflected in increased bone 
biomarkers, correlated with reduced bone mass, suggesting that dysregulation of bone 
turnover was accelerating bone loss in this population. 
Chronic immune activation in HIV is associated with increased AIDS and non-
AIDS morbidities and mortalities [39-43]. Bone loss, osteopenia and osteoporosis are 
among the consequences of residual HIV-associated immune hyperactivation [44]. 
Previous studies have demonstrated the associations between pro-inflammatory 
cytokines, such as IL-6 and TNF-, and bone turnover dysregulation, reflected in 
increased and/or uncoupled bone resorption and formation markers [45-47]. Here we 
observed a trend toward a positive association between pro-inflammatory cytokines and 
bone turnover markers, suggesting that this may be a potential mechanism provoking 
bone demineralization in people living with HIV. 
To the best of our knowledge, this is the largest cohort evaluating bone health 
status among perinatally HIV-infected adolescents in resource-limited settings. Other 




endpoints that we believe to be a more accurate assessment of bone mass in adolescents 
with HIV than the BMD and BMD Z-scores. We were able to use DXA scanners from 
the same manufacturer (Lunar-GE) for all participating sites. We also performed the 
special laboratory measurements, including bone biochemical markers and pro-
inflammatory cytokines at a single central laboratory. Our study is limited by its cross-
sectional design. Furthermore, the number of adolescents with low bone mass was not 
large and likely contributed to the lack of strong associations between bone turnover and 
immune activation markers. Our bone densitometry was performed on the lumbar spine, 
which is mostly trabecular bone, therefore, the results may not be applicable to other 
parts of the body, particularly the hip or proximal femur, which are mostly cortical bone. 
Performing total body bone densitometry may have overcome this limitation, but it would 
have been very costly, and importantly, exposed these young people to greater amounts 
of radiation. Finally, we had to use Thai norms for Indonesian adolescents because lack 
of Indonesian norms, but they constituted a small proportion (6%) of the participants. 
 In conclusion, adverse bone health affects about 10% of Asian children and 
adolescents perinatally infected with HIV. Individuals with older age, female sex, low 
BMI, boosted PI exposure, and poor immunological status before ART initiation were at 
higher risk of low bone mass despite effective treatment. Dysregulation of bone turnover 
was associated with bone demineralization, while there was a trend towards a positive 
association between immune activation and bone turnover markers. Prospective research 
would be needed to monitor for long-term consequences of bone mass deterioration, 
particularly bone fracture, which may occur in the fourth to fifth decades of life. 




risk young people with HIV who might benefit from interventions to promote long-term 
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(n = 396) 
BMD Z-score  
<-2 (n = 65) 
BMD Z-score  
>-2 (n = 331) 
Pb 
Demographic characteristics 
Age (year) 15.0 (13.3-16.9) 16.1 (14.5-18) 14.7 (13.1-16.8) <0.001 
Female sex 226 (57.1) 33 (50.8) 193 (58.3) 0.26 
Anthropometric parameters 
WAZ 
   WAZ <-1.5 
-0.9 (-1.5 to 0.1) 
104 (26.3) 
-1.7 (-2.3 to -1) 
39 (60) 





   HAZ <-1.5 
-0.8 (-1.6 to -0.1) 
102 (25.8) 
-1.4 (-2.3 to 0.61) 
30 (46.2) 














Tanner stage 3-5 290 (73.2) 47 (72.3) 243 (73.4) 0.85 
HIV-specific characteristics 
WHO clinical stage 




















CD4+ percentage prior 
to ART (%) 
12.8 (3.0-20.1) 5 (1.0-14.0) 14 (4.3-21.0) <0.001 
History of ART 

































Duration of ART 
(year) 
Duration of NNRTI 
(year) 


















Current CD4+ T-cell 
count (cells/mm3) 
734 (581-907) 711 (550-858) 735 (587-917) 0.14 
Lifestyle characteristics 
PAQ scorec (out of 5) 1.8 (1.4-2.5) 1.8 (1.4-2.5) 1.8 (1.4-2.5) 0.89 
Sun exposure 
durationd (hour/day) 












(n = 396) 
BMD Z-score  
<-2 (n = 65) 
BMD Z-score  























Ever smoking 21 (5.3) 4 (6.2) 17 (5.2) 0.75 
Ever drinking alcohol 16 (4.1) 1 (1.5) 15 (4.6) 0.26 
 
Abbreviations: ART, antiretroviral therapy; BMD, bone mineral density; BMI, body mass index; 
EFV, efavirenz; HAZ, height for age Z-score; NNRTI, non-nucleoside reverse transcriptase 
inhibitor; PAQ, physical activity questionnaire; PI, protease inhibitor; TDF, tenofovir disoproxil 
fumarate; WAZ; weight for age Z-score; WHO, World Health Organization. 
 
aData were presented as n (%) for categorical data and median (IQR) for continuous data.  
bThe comparisons were performed using Chi-square and Wilcoxon rank sum tests for categorical 
and continuous data, respectively.  
c The analysis was based on 363 adolescents whose data were available. 





























Table 2. Laboratory results and bone turnover markers among perinatally HIV-





(n = 396) 
BMD Z-score <-2 
(n = 65) 
BMD Z-score >-2 
(n = 331) 
Pb 
Laboratory tests related to bone metabolism 
25-OHD (ng/ml) 26.3 (20.8-33.0) 24.9 (20.0-33.3) 26.7 (21.0-32.8) 0.63 
iPTH (pg/ml)  41.7 (33.2-55.8) 41.7 (32.9-53.1) 41.4 (33.3-56.3) 0.78 
Alkaline phosphatase 
(U/l) 
178 (116-263) 213 (124-281) 173 (116-262) 0.20 
Calcium (mg/dl) 9.5 (9.2-9.8) 9.5 (9.3-9.9) 9.5 (9.2-9.8) 0.04 
Phosphorus (mg/dl) 4.3 (3.9-4.9) 4.4 (3.8-4.9) 4.3 (3.9-4.8) 0.74 
Bone turnover markers 
CTX (ng/l) 1270 (860-1,810) 1300 (890-1,880) 1270 (850-1,790) 0.26 
PINP (μg/l) 337 (153-621) 407 (153-678) 328 (153-611) 0.44 
 
Abbreviations: 25-OHD, 25-hydroxyvitamin D; BMD, bone mineral density; CTX, C-terminal 
cross-linked telopeptide of type I collagen (bone resorption marker); iPTH, intact parathyroid 
hormone; PINP, procollagen type I amino-terminal propeptide (bone formation marker). 
 
aData were presented as n (%) for categorical data and median (IQR) for continuous data.  
bThe comparisons were performed using Chi-square and Wilcoxon rank sum tests for categorical 

















Table 3. Factors associated with low bone mass among perinatally HIV-infected Asian adolescents. 
 
Characteristics BMD Z-scores  BMAD Z-scores 






 Adjusted mean 
difference 
(95% CI) 













0.01  -0.07  
(-0.13,-0.02) 
<0.001  -0.07  
(-0.12, -0.02) 
0.01  -0.06  
(-0.11,-0.01) 
0.02 
            
Female sex 0.02  
(-0.27, 0.32) 
0.88  - -  -0.45  
(-0.69, -0.21) 
<0.001  -0.53  
(-0.77,-0.30) 
<0.001 





<0.001  -1.24  
(-1.55,-0.93) 
<0.001  -0.77  
(-1.05,-0.5) 
<0.001  -0.81  
(-1.09,-0.54) 
<0.001 
            




<0.001  - -  0.11  
(-0.16, 0.38) 
0.44  - - 
            
WHO clinical 
stage 4 prior to 
ART (vs. 1-3) 
-0.41  
(-0.69, -0.12) 
0.01  -0.29  
(-0.6,0.03) 
 
0.09  -0.25  
(-0.49, -0.01) 









0.03  -0.28  
(-0.55,-0.01) 
0.04  -0.15  
(-0.39, 0.10) 
0.24  - - 
            
Duration of 




0.14  - -  0.02  
(-0.01, 0.06) 
0.22  - - 
            




<0.001  -0.59  
(-0.85,-0.32) 
<0.001  -0.69  
(-0.97,-0.4) 







Table 3. Factors associated with low bone mass among perinatally HIV-infected Asian adolescents (cont.) 
 
Characteristics BMD Z-scores  BMAD Z-scores 






 Adjusted mean 
difference 
(95% CI) 














0.95  - -  -0.06  
(-0.64, 0.52) 
0.83  - - 
 
Abbreviations: ART, antiretroviral treatment; BMAD, bone mineral apparent density; BMD, body mineral density; BMI, body mass index; 95% 











BMD Z-score  BMAD Z-score 





difference (95% CI)a 





difference (95% CI)b 
P 
CTX -0.026  
(-0.052, 0.002) 
0.07 -0.029  
(-0.048, 0.003) 
0.08  0.0013  
(-0.0120, 0.0145) 
0.99 -0.0286  
(-0.0572, -0.0095) 
0.02 
          
PINP -0.015  
(-0.031, 0.001) 
0.07 -0.029  
(-0.038, -0.004) 
0.02  0.0002  
(-0.0225, 0.0230) 




Abbreviations: BMD, bone mineral density; BMAD, bone mineral apparent density; CTX, C-terminal cross-linked telopeptide of type I collagen 
(bone resorption marker); PINP, procollagen type I amino-terminal propeptide (bone formation marker). 
 
aMultivariable model was adjusted for age, BMI, history of receiving boosted PI, CD4+ percentage prior to ART. 






Supplemental Table 2. Association between pro-inflammatory cytokines and bone turnover markers among perinatally HIV-




(per 10% increase) 
CTX  PINP 
Percentage change 





change in geometric 
mean (95% CI)a 
P  Percentage change 





change in geometric 
mean (95% CI)b 
P 
Interleukin-1 0.40  
(0.06, 0.76) 
0.02 0.14  
(-0.15, 0.42) 
0.35  0.42  
(-0.18, 1.04) 
0.17 - - 
          
Interleukin-1β 0.30  
(0.01, 0.57) 
0.04 0.04  
(-0.19, 0.27) 
0.76  0.42  
(-0.07, 0.91) 
0.09 0.02  
(-0.35, 0.39) 
0.90 
          
Interleukin-6 0.20  
(-0.19, 0.58) 
0.32 - -  0.50  
(-0.18, 1.17) 
0.15 - - 





0.11 - -  0.24  
(-0.11, 0.60) 
0.19 - - 
 
Abbreviations: CTX, C-terminal cross-linked telopeptide of type I collagen (bone resorption marker); PINP, procollagen type I amino-terminal 
propeptide (bone formation marker). 
 
aMultivariable model was adjusted for age, sex, history of receiving tenofovir disoproxil fumarate, duration of antiretroviral treatment and intact 
parathyroid hormone level. 




Figure 1. Comparisons of lumbar spine bone mineral density and bone mineral 
apparent density for HIV-infected and healthy adolescents, stratified by sex. 
 
 
Note: (A) represents the comparison of BMD (g/cm2) for HIV-infected male adolescents with 
healthy males; (B) represents the comparison of BMD (g/cm2) for HIV-infected female 
adolescents with healthy females; (C) represents the comparison of BMAD (g/cm3) for HIV-
infected male adolescents with healthy males; and (D) represents the comparison of BMAD 
(g/cm3) for HIV-infected female adolescents with healthy females. 
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EFFECTS ON BONE TURNOVER AND BONE MINERAL DENSITY 
AMONG PERINATALLY HIV-INFECTED ADOLESCENTS 
 
Tavitiya Sudjaritruk1,2,3, Torsak Bunupuradah3, Linda Aurpibul4, Pope Kosalaraksa5, Nia 
Kurniati6, Wasana Prasitsuebsai3, Jiratchaya Sophonphan3, Jintanat Ananworanich7, and 




1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 
Baltimore, Maryland, USA 
2 Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, 
Thailand 
3 HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand 
4 Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand  
5 Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand 
6 Department of Child Health, Cipto Mangunkusumo General Hospital, Jakarta, 
Indonesia 
7 The Henry M. Jackson Foundation for the Advancement of Military Medicine, the U.S. 
Military HIV Research Program, Maryland, USA 




This chapter has been published as:  
Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai 
W, Sophonphan J, Ananworanich J, Puthanakit T; Bone-D Study Group. 
Hypovitaminosis D and hyperparathyroidism: Effects on bone turnover and bone mineral 
density among perinatally HIV-infeted adolescents. AIDS 2016;30:1059-67. 
 






Objectives: The impact of hypovitaminosis D and secondary hyperparathyroidism on 
bone mineral density (BMD) in the setting of pediatric HIV infection remains unclear. 
This study aimed to determine the prevalence of hypovitaminosis D and 
hyperparathyroidism and their effects on bone turnover and BMD among HIV-infected 
adolescents in Southeast Asia.  
Design: A multicenter, cross-sectional study evaluating bone health and vitamin D 
metabolism in HIV-infected adolescents in Thailand and Indonesia. 
Methods: Perinatally HIV-infected adolescents aged 10-18 years on antiretroviral 
therapy with virologic suppression were enrolled. Serum 25-hydroxyvitamin D, intact 
parathyroid hormone, and bone turnover markers (C-terminal cross-linked telopeptide of 
type I collagen and procollagen type I amino-terminal propeptide) were assessed; 25- 
hydroxyvitamin D less than 20 ng/ml and intact parathyroid hormone more than 65 pg/ml 
were defined as hypovitaminosis D and hyperparathyroidism, respectively. Lumbar spine 
(L2-L4) BMD Z-score -2 or less was defined as low BMD.  
Results: Of 394 adolescents, 57% were women. The median age [interquartile range 
(IQR)] was 15.0 (13.3-16.9) years. The prevalence of hypovitaminosis D, 
hyperparathyroidism, and both conditions were 21% [95% confidence interval (CI): 17-
25%), 17% (95% CI: 13-20%) and 5% (95% CI: 3-7%), respectively. Adolescents with 
hypovitaminosis D and secondary hyperparathyroidism had the highest median bone 
resorption (C-terminal cross-linked telopeptide of type I collagen: 1610 vs. 1270 ng/l; 




μg/l; P=0.02) markers, and the greatest proportion of low BMD (42 vs. 15%; P=0.01) 
compared with the rest of the cohort. 
Conclusion: Hypovitaminosis D complicated with secondary hyperparathyroidism was 
associated with increased bone turnover and bone loss. Early treatment of 




















In recent years, hypovitaminosis D, as measured by serum 25-hydroxyvitamin D 
(25-OHD) below 20 ng/ml, has emerged as a research priority among HIV-infected 
populations because of its association with HIV disease progression [1] and all-cause 
mortality [2]. In addition, this condition plays a critical role in the pathogenesis of several 
long-term, non-AIDS-related complications, including adverse bone health, 
cardiovascular disease, insulin resistance and diabetes mellitus [3-7]. However, most 
studies were conducted in Western and developed countries, and such conditions in 
resource-limited settings have been poorly studied.  
High prevalence of hypovitaminosis D among HIV-infected individuals, both 
adults (13-69%) [8] and youth (25-77%), have been observed [9-11]. Numerous factors 
could contribute to this condition, including traditional factors such as female sex, dark 
skin pigmentation, high body mass index (BMI), physical inactivity, reduced sun 
exposure and winter season [6,8,10,12-14], as well as HIV-related factors such as 
advanced stage of disease, exposure to certain antiretroviral drugs, for example, efavirenz 
and ritonavir-boosted protease inhibitors, and immune activation [6,8,12,14]. Yet, it is 
usually difficult to differentiate the direct effects of each factor on vitamin D status in 
HIV-infected persons. 
Vitamin D is critical for calcium homeostasis and bone metabolism. It promotes 
calcium absorption from the gut, preserves adequate calcium in blood circulation, aids 
bone growth and remodeling, and maintains normal bone mineralization and strength 
[15,16]. Low vitamin D level can result in low serum calcium levels [17], which 
stimulate parathyroid glands to release parathyroid hormone (PTH), causing secondary 




levels in the blood, increased PTH levels thereafter accelerate calcium mobilization from 
the labile bone pool via osteoclast activation, together with other mechanisms [15,16]. 
Thus, hypovitaminosis D can contribute to elevated PTH that may result in bone 
demineralization, and with time, bone loss [15,16]. This study aimed to investigate the 
prevalence hypovitaminosis D and secondary hyperparathyroidism, as well as their 
pathological effects, on bone turnover and bone mineral density (BMD) among HIV-








Methods and measurements 
Study design and participants  
 This is a substudy of a multicenter, cross-sectional study evaluating bone health 
outcomes and vitamin D metabolism in perinatally HIV-infected Asian adolescents. The 
study was conducted at four pediatric HIV centers in Thailand (latitude 13.75°N) and 
Indonesia (latitude 6.18°S), including the HIV Netherlands Australia Thailand 
collaboration in Bangkok (BKK), the Faculty of Medicine and Research Institute for 
Health Sciences in Chiang Mai, and Srinagarind Hospital, Khon Kaen University in Khon 
Kaen; the Cipto Mangunkusumo General Hospital in Jakarta. Since BKK and Jakarta are 
capital cities, and Chiang Mai and Khon Kaen are provincial cities, we categorized these 
sites as urban (BKK and Jakarta) and rural (Chiang Mai and Khon Kaen) regions. 
Perinatally HIV-infected adolescents (aged 10-18 years) who had virologic suppression 
(plasma HIV-1 RNA <400 copies/ml, within the past 6 months) on antiretroviral therapy 
(ART) were enrolled. Adolescents with previous bone abnormality or having other 
diseases that affect bone health were excluded. We also precluded adolescents who were 
on treatment of low bone mass, reported taking vitamin D supplements, or received 
medications affecting bone density and metabolism. Written informed assent and consent 
were obtained from adolescents and their caregivers as appropriate. The study was 
reviewed and approved by the local institutional review boards at all sites.  
 
Data collection and clinical assessments 
Demographic characteristics and HIV-related parameters of each participant were 
retrieved from medical records. Anthropometric measurements, Tanner stage evaluation, 




height-for-age Z-scores were calculated using a Thai normative reference [18], and BMI 
percentile was computed based on the US Centers for Disease Control and Prevention 
reference [19]. Information regarding sun exposure duration (h/ day) and physical activity 
levels [score 1 (low) to 5 (high)] were assessed using standard questionnaires [20].  
 
Laboratory measurements 
Overnight fasting blood samples for 25-OHD, intact parathyroid hormone (iPTH), 
calcium, phosphorus, alkaline phosphatase and bone turnover markers were collected 
between 8:00 – 10:00 a.m. to prevent circadian variation of biochemical markers of bone 
turnover. Serum was obtained and stored at -70°C until laboratory analysis. An 
automated electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, 
Germany), measured on a Cobas® e411 immunoassay analyzer (Roche Diagnostics, 
Mannheim, Germany), was used to quantify 25-OHD, iPTH, bone resroption marker (C-
terminal cross-linked telopeptide of type I collagen; CTX), and bone formation marker 
(procollagen type I amino-terminal propeptide; PINP). These bone metabolism-related 
markers were analyzed at a single reference site, the Research Institute for Health 
Sciences, Chiang Mai University (Chiang Mai, Thailand) by a single technician. The 
other laboratory parameters were measured at each local site. According to the Endocrine 
Society, vitamin D insufficiency (VDI) and hypovitaminosis D were defined as 25-OHD 
level between 20 and 29.9 ng/ml and below 20 ng/ml, respectively [21]. Serum iPTH 
level above 65 pg/ml was considered to be high and defined as hyperparathyroidism [22]. 




U/l (women). The normal range of calcium was 8.4-10.2 mg/dl, and phosphorus was 3.3-
5.4 mg/dl (age 10-15 years) and 2.4-4.4 mg/dl (age >15 years).  
 
Bone mineral density assessment 
BMD of the lumbar spine (L2 to L4) was evaluated by dual-energy X-ray 
absorptiometry technique (Lunar; General Electric Healthcare, Madison, Wisconsin, 
USA) by radiology technologists at all sites. The scans were analyzed using enCORE 
software version 14.1 (encore, General Electric Healthcare, Madison, Wisconsin, USA). 
BMD Z-scores comparing the absolute BMD results of participants to the average results 
of Thai adolescents of the same age and sex were calculated [23]. A Z-score -2 or less 
was defined as low BMD according to the 2013 Pediatric Official Positions of the 
International Society for Clinical Densitometry [24]. 
 
Statistical analysis 
The prevalence of hypovitaminosis D (25-OHD <20 ng/ml) and 
hyperparathyroidism (iPTH >65 pg/ml), together with 95% confidence intervals (CI), 
were calculated. The comparisons of prevalence of hypovitaminosis D between regions 
(urban vs. rural) and across seasons [hot (April to June) vs. rainy (July to October) vs. 
cool (November to December)] were performed using chi-square test. Participant 
characteristics, stratified by 25-OHD levels (25-OHD <20; 20-29.9; and >30 ng/ml), 
were evaluated by chi-square and Kruskal-Wallis tests for categorical and continuous 
variables, respectively. Univariate linear regression was performed to identify factors 




model were included in the multivariable analysis. Variables suspected to be potential 
effect modifiers of the associations were evaluated. The magnitudes of associations were 
summarized with mean differences and adjusted mean differences for univariate and 
multivariable analyses, respectively.  
To determine the effects of hypovitaminosis D and secondary 
hyperparathyroidism on bone turnover and BMD, we classified our adolescents into six 
subgroups according to their vitamin D and PTH statuses, as adolescents with 
hypovitaminosis D and hyperparathyroidism; hypovitaminosis D and normal iPTH level; 
VDI and hyperparathyroidism; VDI and normal iPTH level; normal vitamin D status and 
hyperparathyroidism; and normal vitamin D and PTH statuses. The comparisons of 
laboratory results, bone turnover markers and BMD across subgroups were conducted 
using chi-square test for categorical variables and Kruskal-Wallis test (comparing across 
six subgroups) or Wilcoxon rank sum test (comparing two specific subgroups) for 
continuous variables, as appropriate.  
All statistical analyses were performed using Stata statistical software, version 13. 
(StataCorp LP, College Station, Texas, USA). A two-sided P <0.05 was considered 












There were 394 adolescents, of whom 57.1% were women, with a median age of 
15.0 years, enrolled between April and December 2014. The enrollment occurred during 
the hot (n = 75; 19.0%), rainy (n = 186; 47.2%), and cool (n = 133; 33.8%) seasons. 
Approximately three- quarters of adolescents (73.1%) reached Tanner stage 3-5. Nearly 
half (43.6%) were in WHO clinical stage 4, with a median CD4+ T-cell percentage of 13 
before ART initiation. At entry, 140 adolescents (35.5%) were on boosted protease 
inhibitor-based regimens, of which 81% were lopinavir/ritonavir based. The median 
duration of ART use was 9.3 years and the median CD4+ T-cell count was 734 cells/mm3. 
Among those with available data (n = 245), the median duration of sun exposure was 0.4 
h/ day that was different between individuals with hypovitaminosis D, VDI, and normal 
vitamin D status (P = 0.03). The characteristics of participants stratified by vitamin D 
status are summarized in Table 1.  
 
Prevalence of hypovitaminosis D and hyperparathyroidism 
The median 25-OHD level was 26.3 ng/ml. Overall, hypovitaminosis D (25-OHD 
<20ng/ml) was documented in 83 adolescents (21.1%; 95% CI: 17.0-25.1%) and 
approximately half (44.2%; 95% CI: 39.2-49.1%) had VDI (25-OHD = 20-29.9 ng/ml). 
The prevalence of hypovitaminosis D did not vary between regions (urban: 23.6%; rural: 
19.3%; P = 0.31) or across seasons (hot: 18.7%; rainy: 21.0%, cool: 22.6%; P = 0.80). 
The median iPTH level was 41.7 pg/ml, and 66 adolescents (16.8%; 95% CI: 13.1-




hypovitaminosis D group and 36 (20.7%) in VDI group developed secondary 
hyperparathyroidism. 
 
Associated factors of vitamin D level and its relationship with parathyroid hormone 
In the univariate analysis, boosted protease inhibitor regimens (P <0.001) and 
current CD4+ T-cell count (P = 0.01) were positively associated with 25-OHD level, 
whereas negative associations were observed for female sex (P <0.001) and BMI (P 
<0.001). In the multivariable analysis, boosted protease inhibitor regimens remained 
independently and positively associated with 25-OHD level (P <0.001), whereas female 
sex (P <0.001) and higher BMI (P = 0.04) were independently and negatively associated 
with 25-OHD level. The iPTH was inversely correlated with 25-OHD level in both the 
univariate (P <0.001), and multivariable analyses (P = 0.001) (Table 2).  
 
The effects of vitamin D and parathyroid hormone on bone turnover  
Adolescents with hypovitaminosis D (25-OHD <20 ng/ml) and secondary 
hyperparathyroidism (iPTH >65 pg/ml) had the highest median levels of bone resorption 
(CTX: 1610 vs. 1270 ng/l; P = 0.04) and bone formation (PINP: 572 vs. 330 μg/l; P = 
0.02) markers compared with the rest of the cohort (Figure 1).  
The comparison of laboratory results related to bone metabolism within each 
vitamin D group are summarized in Table 3. Among adolescents with hypovitaminosis D, 
individuals with secondary hyperparathyroidism had higher alkaline phosphatase (253 vs. 
173 U/l; P = 0.02) and phosphorus levels (4.8 vs. 4.3 mg/dl, P = 0.03), but maintained 




(Table 3). In addition, biomarkers for bone turnover, both CTX (1610 vs. 1160 ng/l; P = 
0.02) and PINP (572 vs. 289 μg/l; P = 0.01) were higher in adolescents with secondary 
hyperparathyroidism in comparison with individuals without this condition. Similarly, 
among adolescents with VDI (25-OHD 20-29.9 ng/ml), individuals with secondary 
hyperparathyroidism had greater levels of bone turnover markers compared with those 
with normal PTH status (CTX: 1610 vs. 1200 ng/l; P = 0.01; PINP: 430 vs. 342 μg/l; P = 
0.04) (Table 3). 
 
The effects of vitamin D and parathyroid hormone on bone mineral density  
The proportion of low BMD varied considerably across six subgroups (P = 0.03), 
with the highest percentage in the group with hypovitaminosis D and secondary 
hyperparathyroidism (42.1%) (Figure 2). Additionally, the median BMD Z-score was 
lowest in this group as compared with the rest of the cohort (-1.2 vs. -0.7; P = 0.10) 
(Table 3).   
When comparing within each vitamin D group, the proportion of low BMD in the 
group with hypovitaminosis D was greater in adolescents who had secondary 
hyperparathyroidism compared with those without this condition (42.1 vs. 12.7%; P = 
0.01). However, such difference was not observed in the groups with VDI and normal 









 One-fifth of the perinatally HIV-infected adolescents in this cross-sectional cohort 
had hypovitaminosis D. Boosted protease inhibitor regimens was positively associated 
with 25-OHD levels, whereas female sex, high BMI and elevated iPTH were negatively 
associated. Adolescents with hypovitaminosis D along with secondary 
hyperparathyroidism had significantly elevated bone turnover markers and substantially 
great proportion of low BMD, whereas adolescents with VDI and secondary 
hyperparathyroidism had increased bone turnover markers that did not result in 
reductions in BMD Z-scores.  
Although our study settings, Thailand and Indonesia, are located in tropical 
climate zones, the prevalence of hypovitaminosis D (25-OHD <20 ng/ml) among our 
adolescents was relatively high (21%) and comparable with those of healthy, HIV-
uninfected children and adolescents living in Thailand (20%) and Indonesia (15%) 
[25,26]. However, when compared with HIV-infected children and adolescents living in 
Western countries, the prevalence of hypovitaminosis D documented in our study was 
much lower [12,13]. The dissimilarity in latitude and seasons of study settings, 
race/ethnicity of study populations, definition of hypovitaminosis D, and assay 
techniques for 25-OHD might contribute to the difference in prevalence of 
hypovitaminosis D between ours and the Western studies. A US study (Philadelphia; 
latitude 39.96°N) revealed that the prevalence of hypovitaminosis D (25-OHD <11 
ng/ml) among their HIV-infected children and adolescents was 36%, which was 
significantly greater than that seen in healthy controls from the same geographic area 




infected group was significantly higher than in the HIV-uninfected group (83 vs. 37%; P 
<0.001) [12]. A French study (Paris; latitude 48.50°N), where the majority of participants 
(68%) were of African or African-French origin and the study period was during their 
winter/spring, reported a 25% prevalence of hypovitaminosis D (25-OHD <10 ng/ml) 
among their children and young adults living with HIV. Yet, this number was 
significantly lower than that observed in healthy controls living in the same area with 
similar skin phototype (54%, P <0.001) [13].  
Important traditional factors associated with hypovitaminosis D among HIV 
individuals include Black race or Hispanic ethnicity, older age, female sex, high BMI, 
physical inactivity and low exposure to sunlight [10,14,27-29]. In this study, we 
demonstrated the significant associations between female sex and high BMI with low 25-
OHD levels, whereas physical activity levels showed a trend of positive association that 
did not reach statistical significance when adjusting for confounders. Although we 
observed a difference in duration of sun exposure between adolescents with 
hypovitaminosis D, VDI and normal vitamin D status, we could not assess the association 
between short duration of sun exposure and decreased 25-OHD levels in this study 
because of missing data.  
Several antiretroviral medications might also be associated with vitamin D status 
[28,30-32]. In this study, we found a positive association between ritonavir-boosted 
protease inhibitors and 25-OHD levels. A Dutch study noted that White HIV-infected 
adults on protease inhibitors had higher levels of 25-OHD compared with individuals 
exposed to nonnucleoside reverse transcriptase inhibitors or treatment-naïve persons [33]. 




bioactivation of 25-OHD to 1,25-dihydroxyvitamin D [1,25-(OH)2D] in the kidneys [34]. 
Therefore, individuals on ritonavir-boosted protease inhibitors may appear to have 
adequate 25-OHD levels, but they generally have decreased 1,25-(OH)2D levels. 
Unfortunately, we were not able to measure 1,25-(OH)2D.    
We found that 17% of our adolescents had hyperparathyroidism (iPTH >65 
pg/ml), of which 5% co-occurred with hypovitaminosis D; 9% with VDI; and 3% with 
normal vitamin D status. Hyperparathyroidism in our adolescents was inversely 
associated with vitamin D level as has been shown in other studies [9,35,36]. 
Hypovitaminosis D is one of the common causes of secondary hyperparathyroidism 
[37,38]. The possible explanation for the hyperparathyroidism independent from 
hypovitaminosis D and VDI found in our study may be related to inadequate calcium 
intake. The median daily calcium intake in adolescents with this condition (205 mg/day; 
data not shown) was much lower than the recommended dietary allowance for calcium 
for this age group (1300 mg/day) [39]. Other possible contributing factors include poor 
calcium absorption from the gut and other comorbidities, particularly chronic renal 
failure. However, we excluded participants with documented kidney diseases from this 
study and are unable to further assess calcium absorption. 
Interestingly, we found dose-response relationships of vitamin D and PTH status 
on bone turnover markers and BMD in this study. To clarify, we found that, among 
adolescents with hypovitaminosis D, individuals with secondary hyperparathyroidism 
had significantly higher bone resorption and formation markers, and a greater proportion 
had low BMD (BMD Z-score <-2) compared with those without hyperparathyroidism. 




populations [40,41]. A study of postmenopausal British women older than 60 years with 
established osteoporosis found that individuals with hypovitaminosis D and secondary 
hyperparathyroidism had significantly higher bone formation (bone alkaline phosphatase 
and osteocalcin) and bone resorption (urine-free deoxypyridinoline) markers, and 
considerably lower hip BMD compared with those who had hypovitaminosis D without 
hyperparathyroidism, and those without hypovitaminosis D [40]. Another study 
conducted in Indo-Asian middle-aged adults with vitamin D deficiency living in the 
United Kingdom revealed that individuals who had secondary hyperparathyroidism had 
significantly lower femoral neck and distal radius BMD Z and T-scores compared with 
those without hyperparathriodism [41]. Therefore, our findings support that 
hypovitaminosis D and secondary hyperparathyroidism were associated with acceleration 
of bone turnover that may aggravate reduction in bone density in HIV-infected 
population.  
Furthermore, among adolescents who had VDI, we observed that those with 
secondary hyperparathyroidism had a significant elevation in bone turnover markers, but 
did not demonstrate higher prevalence of low BMD in comparison with the group 
without hyperparathyroidism. We hypothesized that these individuals might be able to 
keep net change of bone remodeling process in their skeletal system or the level of 
vitamin D might not be low enough to cause reduced BMD.  
This study contained some limitations. First, our study was conducted only in 
tropical regions, and the findings may have limited generalizability to settings in different 
geographic locations. Second, although we found several significant associated factors 




is limited. Nevertheless, our study had several strengths. To our knowledge, this study is 
among the first studies investigating the effects of hypovitaminosis D and secondary 
hyperparathyroidism on bone metabolism and bone density among perinatally HIV-
infected adolescents in Asia. Furthermore, laboratory measures related to bone 
metabolisms, including 25-OHD, iPTH and bone biochemical markers, were measured at 
a single laboratory center. Therefore, the consistency and comparability of the results can 
be ensured.  
In conclusion, among perinatally infected with HIV adolescents living in tropical 
countries, hypovitaminosis D is relatively high. The deficiency of vitamin D complicated 
by secondary hyperparathyroidism was associated with accelerated bone turnover and 
bone demineralization. Monitoring for vitamin D and PTH status may be important for 
individuals at high risk for hypovitaminosis D. Vitamin D supplementation in persons 
with deficiency of vitamin D before secondary hyperparathyroidism develops may be 
necessary for preventing future bone demineralization. The experimental study to 
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Table 1. Characteristics of perinatally HIV-infected Asian adolescents by vitamin D status. 
 
Characteristicsa Total 
(n = 394) 
25-OHD <20 ng/ml 
(n = 83) 
25-OHD 20-29.9 ng/ml 
(n = 174) 
25-OHD >30 ng/ml 
(n = 137) 
Pb 
Demographic characteristics 
Age (year) 15.0 (13.3-16.9) 14.9 (12.9-17.2) 15.0 (13.6-16.7) 15.2 (13.3-16.9) 0.90 
Female sex 225 (57.1) 61 (73.5) 103 (59.2) 61 (44.5) <0.001 




-0.9 (-1.6 to 0.1) 
104 (26.4) 
-0.5 (-1.6 to 0.4) 
21 (25.3) 
-0.8 (-1.4 to 0.1) 
42 (24.1) 






-0.8 (-1.6 to -0.1) 
102 (25.9) 
-0.8 (-1.5 to 0.1) 
20 (24.1) 
-0.8 (-1.4 to 0.1) 
41 (23.6) 
















Tanner stage 3-5 288 (73.1) 60 (72.3) 129 (74.1) 99 (72.3) 0.92 
HIV-specific characteristics 
















CD4+ percentage prior to ART 13 (3-20) 11 (3-22) 13 (3-21) 14 (4-20) 0.87 
Current ART regimen 
NNRTI based 
PI based 



















Duration of ART (year) 9.3 (6.9-11.5) 8.8 (6.3-11.6) 9.3 (7.4-11.4) 9.8 (6.7-11.5) 0.69 
Current CD4+ T-cell count 
(cell/mm3) 








Table 1. Characteristics of perinatally HIV-infected Asian adolescents by vitamin D status (cont.) 
 
Characteristicsa Total 
(n = 394) 
25-OHD <20 ng/ml 
(n = 83) 
25-OHD 20-29.9 ng/ml 
(n = 174) 
25-OHD >30 ng/ml 
(n = 137) 
Pb 
Lifestyle characteristics 
Sun exposure durationc 
(hour/day) 
0.4 (0.2-0.8) 0.3 (0.2-0.6) 0.4 (0.2-0.8) 0.5 (0.2-1.0) 0.03 
PAQ scored (out of 5) 1.8 (1.4-2.5) 1.7 (1.3-2.4) 1.8 (1.4-2.5) 1.9 (1.4-2.6) 0.37 
 
Abbreviations: 25-OHD, 25-hydroxyvitamin D; ART, antiretroviral therapy; HAZ, height for age Z-score; NNRTI, non-nucleoside reverse 
transcriptase inhibitor; PAQ, physical activity questionnaire; PI, protease inhibitor; WAZ; weight for age Z-score.  
 
aData were presented as n (%) for categorical data and median (IQR) for continuous data.  
bThe comparisons were performed using Chi-square and Kruskal-Wallis tests for categorical and continuous data, respectively.  
cThe analysis was based on 245 adolescents whose data were available. 




Table 2. Factors associated with 25-hydroxyvitamin D levels among perinatally HIV-infected adolescents.  
 
 Characteristics  Univariate analysis  Multivariable analysis 
Mean difference  
(95% CI) 
P  Adjusted mean difference 
(95% CI) 
P 
Age (per 1 year increased) 0.03 (-0.38, 0.43) 0.90  - - 
Female sex -5.18 (-7.06, -3.30) <0.001  -4.82 (-6.84, -2.80) <0.001 
BMI -0.43 (-0.69, -0.17) <0.001  -0.31 (-0.59, -0.02) 0.04 
PAQ score (per 1 score increased) 2.38 (-0.39, 5.14) 0.09  1.14 (-1.61, 3.89) 0.42 
WHO stage 4 prior to ART (vs. stage 1-3) -0.24 (-2.23, 1.75) 0.81  - - 
Current ART regimen (boosted PI vs. NNRTI/others) 3.97 (2.02, 5.92) <0.001  3.62 (1.63, 5.60) <0.001 
Duration of ART (per 1 year increased) 0.14 (-0.15, 0.43) 0.34  - - 
CD4+ prior to ART <15% 0.03 (-0.07, 0.13) 0.57  - - 
Current CD4+ T-cell count  0.005 (0.001, 0.009) 0.01  0.003 (-0.001, 0.007) 0.09 
iPTH level  -0.09 (-0.13, -0.05) <0.001  -0.08 (-0.13, -0.04) 0.001 
 
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; iPTH, intact parathyroid hormone; NNRTI, non-nucleoside reverse 















25-OHD <20 ng/mlb  25-OHD 20-29.9 ng/ml  25-OHD >30 ng/ml Overall 
Pd 
 iPTH >65 
pg/ml 
(n = 19) 
iPTH <65 
pg/ml 
(n = 63) 
Pc  iPTH >65 
pg/ml 
(n = 36) 
iPTH <65 
pg/ml 
(n = 138) 
Pc  iPTH >65 
pg/ml 
(n = 11) 
iPTH <65 
pg/ml 
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25-OHD <20 ng/mlb  25-OHD 20-29.9 ng/ml  25-OHD >30 ng/ml Overall 
Pd 
 iPTH >65 
pg/ml 
(n = 19) 
iPTH <65 
pg/ml 
(n = 63) 
Pc  iPTH >65 
pg/ml 
(n = 36) 
iPTH <65 
pg/ml 
(n = 138) 
Pc  iPTH >65 
pg/ml 
(n = 11) 
iPTH <65 
pg/ml 
(n = 126) 
Pc 
Bone mineral density 
BMD Z-score -1.2  
(-2.4 to -0.3) 
-0.4  
(-1.6 to 0.5) 
0.08  -0.3  
(-1.2 to 0.7) 
-0.8  
(-1.6 to 0.2) 
0.06  -0.4  
(-1.3 to 0.2) 
-0.7  
(-1.6 to 0.0) 
0.50 0.17 

















Abbreviations: 25-OHD, 25-hydroxyvitamin D; BMD, bone mineral density; CTX, C-terminal cross-linked telopeptide of type I collagen (bone resorption 
marker); iPTH, intact parathyroid hormone; PINP, procollagen type I amino-terminal propeptide (bone formation marker). 
 
aData were presented as n (%) for categorical data and median (IQR) for continuous data.  
bOne adolescents missed iPTH result. 
cChi-square and Wilcoxson rank sum tests were used to compare categorical and continuous data, respectively. 
























Note: (A) represents the comparison of C-terminal cross-linked telopeptide of type I collagen (CTX; bone resorption marker) of perinatally HIV-
infected adolescents according to their vitamin D and parathyroid hormone statuses; and (B) represents the comparison of procollagen type I 
amino-terminal propeptide (PINP; bone formation marker) of perinatally HIV-infected adolescents according to their vitamin D and parathyroid 
hormone statuses. 
 










Figure 2. Comparison of the proportion of low bone mineral density among 




Note: Low bone mineral density was defined as lumbar spine BMD Z-score -2 or less. 
 








































Summary of findings 
 Adverse bone health is an important non-communicable disease (NCD) among 
perinatally HIV-infected adolescents receiving antiretroviral treatment (ART) [1,2]. Since 
adolescence is a time of the maximum rapid growth and bone mineral accrual [3,4], the 
impairment of bone mineral acquisition and mineralization during this critical period may 
lead to several serious consequences, particularly osteoporosis and bone fracture, later in 
life [5-7]. In the setting of HIV infection, the pathogenesis of bone mass loss seems to be 
much more complicated than what has been demonstrated in general populations. 
Hypovitaminosis D complicated with secondary hyperparathyroidism can aggravate bone 
demineralization by causing the dysregulation of bone turnover [8]. Moreover, residual 
chronic immune activation and systemic inflammation due to HIV itself may also hasten 
bone turnover which subsequently results in the loss of bone mass [9]. As a consequence, 
all of these traditional risk factors along with HIV-related factors can accelerate the rate 
of bone demineralization and bone mass deterioration in HIV-infected individuals 
compared with their healthy peers [10]. During the past few years, adverse bone health 
problems among people living with HIV have been extensively investigated, but there is 
a dearth of studies specifically focusing on perinatally HIV-infected adolescents living in 
resource-constrained settings. Therefore, the main purpose of this dissertation stemmed 
from the need to assess information regarding the extent of adverse bone health and its 
pathogenesis, together with the magnitude and severity of hypovitaminosis D and its 
pathological impacts on bone mass among perinatally HIV-infected adolescents living in 




 Chapter 3 assessed the prevalence of low bone mass and its relationship with 
abnormal bone turnover among perinatally HIV-infected adolescents with virologic 
suppression on ART. Using dual-energy X-ray absorptiometry (DXA) scan to evaluate 
bone mass, we noted that the prevalence of low bone mass [lumbar spine bone mineral 
density (BMD) Z-score <-2] among adolescents in our cohort was approximately 16%. 
Since about one-fourth of our adolescents were short-for-age (height-for-age Z-score <-
1.5), we adjusted their BMD results by calculating bone mineral apparent density 
(BMAD) to eliminate the effects of height and skeletal size, and found that the 
prevalence of low bone mass (BMAD Z-score <-2) declined to approximately 8%. 
Additionally, we demonstrated that bone mass of our adolescents was much lower than 
those of their age- and sex-matched healthy peers.  
 Furthermore, in our analysis, the traditional factors that included advanced age, 
female sex and low body mass index (BMI), together with HIV-specific factors which 
included boosted protease inhibitor (PI) exposure and low CD4+ prior to ART initiation 
showed a significant association with decreased bone mass in our adolescents. We also 
found that the dysregulation of bone turnover, reflected in the increased in bone 
resorption and formation markers, were independently associated with bone mass 
reduction. Although the results did not attain statistical significance, residual chronic 
immune activation and inflammation by HIV infection, demonstrated by the elevation in 
pro-inflammatory cytokines, showed a trend of positive correlation with the increase in 
bone turnover among our population.  
In summary, our findings highlighted that adverse bone health is not uncommon 




these individuals should be routinely monitored, especially for those at high risk of bone 
demineralization. In addition, the appropriate measures to augment bone mineral 
accretion should be encouraged among this population to prevent the future unfavorable 
and irreversible consequences. 
        In Chapter 4, we explored the prevalence of hypovitaminosis D and 
hyperparathyroidism, as well as their pathological effects on bone turnover and bone 
mass among perinatally HIV-infected adolescents with virologic suppression on ART. 
Although our study settings are located in a tropical climate zone where sunshine is 
considered to be adequate all year long, we demonstrated that approximately 21% and 
44% of our adolescents had hypovitaminosis D [25-hydroxyvitamin D (25-OHD) <20 
ng/ml] and vitamin D insufficiency (VDI; 25-OHD = 20-29.9 ng/ml), respectively. In 
addition, the prevalence of hypovitaminosis D did not vary by season or study setting. Of 
note, about 23% of adolescents with hypovitaminosis D and 21% of those with VDI 
developed secondary hyperparathyroidism [intact parathyroid hormone (iPTH) >65 
pg/ml].  
In the analysis, female sex, high BMI and elevated iPTH demonstrated negative 
associations, while boosted PI regimens showed a positive association with vitamin D 
levels. Interestingly, we found that adolescents with hypovitaminosis D and secondary 
hyperparathyroidism had the highest median bone resorption and bone formation 
markers, as well as the greatest proportion of low bone mass (lumbar spine BMD Z-score 
<-2) compared to the rest of the cohort. Furthermore, we noted dose-response 
relationships of vitamin D and parathyroid hormone (PTH) status on bone turnover and 




secondary hyperparathyroidism had higher bone turnover (both bone resorption and bone 
formation markers), and a greater proportion of low bone mass compared to those 
without hyperparathyroidism. Additionally, among adolescents with VDI, those with 
secondary hyperparathyroidism had greater bone turnover, but did not demonstrate a 
higher proportion of low bone mass compared to individuals with normal PTH status. For 
adolescents with normal vitamin D status (25-OHD >30 ng/ml), the levels of bone 
turnover markers and the proportion of low bone mass were not different between those 
with and without hyperparathyroidism. 
In conclusion, we demonstrated that hypovitaminosis D was prevalent among 
perinatally HIV-infected adolescents, even living in tropical region. The deficiency of 
vitamin D complicated with secondary hyperparathyroidism showed the adverse effects 
on bone turnover and bone mass among these individuals. Thus, the regular monitoring 
of vitamin D and PTH status, especially for those at high risk for hypovitaminosis D, may 
be necessary. Additionally, vitamin D supplements for those with deficiencies, before 
secondary hyperparathyroidism develops, may be important to prevent bone 
demineralization and bone loss.     
   
Lesson learned 
From this dissertation, it is apparent that low bone mass is one of the important 
NCDs among HIV-infected adolescents with perinatally acquired HIV infection. We 
found a marked reduction of bone mass in our adolescents in comparison to healthy 
individuals at the same age and sex. Because, in general, bone mass deterioration is 




populations, most pediatricians and healthcare providers are usually not concerned with 
this condition in children and adolescents under their care. However, in an HIV-infected 
population, particularly in perinatally HIV-infected adolescents who have experienced 
HIV infection since birth and have been exposed to ART for a long duration, these 
individuals may face the earlier occurrence of age-related co-morbidities compared to 
their HIV-uninfected peers. Therefore, the information derived from this dissertation 
would help raise awareness of pediatricians and healthcare providers to evaluate and 
monitor bone health status among their adolescents in clinical practice that would allow 
them to provide earlier diagnosis and promptly treatment if the problem occurs. However, 
because of a cross-sectional study design of this dissertation, the longitudinal trajectory 
of bone mass in this population cannot be assessed. A prospective cohort study may be an 
appropriate study design to address this research question.  
  With the limitation of DXA measurement, which is currently considered a 
standard tool of bone mass measurement in children and adolescents, regarding the issues 
of height and skeletal size, the 2013 International Society for Clinical Densitometry 
recommends that BMD measurements in individuals with short stature or growth delay 
should be adjusted by using BMAD [11]. In this dissertation, we calculated BMAD and 
noticed that the prevalence of low bone mass was declined from 16% (using the 
definition of BMD Z-score <-2) to 8% (using the definition of BMAD Z-score <-2) 
which was comparable to those reported in resource-rich countries [12,13]. This 
information suggests that HIV-infected children and adolescents who are usually short-
for age, the use BMD results to determine low bone mass may underestimate their actual 




prevalence of low bone mass should be evaluated based on BMAD rather than BMD to 
reflect the actual extent of the problem in HIV-infected population. In addition, the 
measurement of true volumetric BMD using quantitative computed tomography (qCT) or 
quantitative magnetic resonance imaging (qMRI) may be better approaches evaluating 
bone health status in this population [14-16].  
It is interesting that while Thailand and Indonesia are sunny countries, nearly 
three-fourths of our HIV-infected adolescents had vitamin D levels lower than the normal 
range (25-OHD <30 ng/ml). Changes in lifestyle, e.g., avoiding direct sunlight exposure, 
using sunscreen and reducing outdoor activities, lack of food fortification with vitamin D, 
and high levels of air pollutions that influence the amount of ultraviolet B radiation may 
be potential factors that increase the risk of vitamin D deficiency among our adolescents. 
Thus, the monitoring of vitamin D status, using 25-OHD measurements, may be 
necessary to be implemented in clinical practice for this population, especially for those 
at high risk for hypovitaminosis D. 
 Additionally, with the information gained from this dissertation, PTH plays a 
significant role in determining bone mass status. We noted that among our HIV-infected 
adolescents with hypovitaminosis D, those with secondary hyperparathyroidism had 
higher bone turnover markers and greater prevalence of low bone mass in comparison to 
those without this condition. Therefore, monitoring of PTH along with 25-OHD levels 
may help identify individuals at high risk of reduced bone mass. However, more evidence 






Public health significance 
As the knowledge regarding adverse bone health among adolescents with 
perinatally acquired HIV infection in resource-constrained countries is scarce, this 
dissertation provides meaningful scientific information on the extent of low bone mass 
problem in this population. Additionally, because our data revealed that low bone mass is 
not uncommon in HIV-infected adolescents, this helps raise awareness and draws clinical 
attention to pediatricians and healthcare providers who might not be familiar with adverse 
bone health problems, a long-term non-AIDS-related comorbidity facing adolescents 
growing up with HIV in the ART era. Furthermore, we also demonstrated significant 
associated factors and possible related mechanisms for bone demineralization in this 
population. Understanding the role of these factors and mechanisms may help healthcare 
providers and policy makers to develop more appropriate strategies to prevent bone loss, 
as well as the feasible interventions to promote bone health for these individuals in their 
public health practice. 
In addition, this dissertation demonstrated the high prevalence of hypovitaminosis 
D and VDI in our HIV-infected adolescents. This information highlights that, despite 
living in tropical countries where there is abundant sunlight all year round, vitamin D 
inadequacy still exists as a public health problem. Moreover, because hypovitaminosis D 
complicated with secondary hyperparathyroidism appears to be associated with an 
increase in bone turnover and the loss of bone mass in our study, routine screening for 
vitamin D and PTH statuses among these adolescents in public health practice may be 
beneficial for pediatricians and healthcare providers to promptly diagnose any laboratory 




possibly prevent long-term unfavorable skeletal outcomes. Nevertheless, additional cost-
effectiveness analyses are required to confirm the benefits of this action plan before 
widespread implementation.  
Lastly, this dissertation may serve as a preliminary study to efficiently move 
toward the more comprehensive researches to confirm the causal relationships, as well as 
to explore the other concealed factors and mechanisms related to adverse bone health 
among adolescents living with HIV in the near future. 
 
Future directions 
 This dissertation emphasizes the importance of adverse bone health problem 
among adolescents with perinatally acquired HIV infection as they survive into 
adulthood. However, because of the cross-sectional study design, it is difficult to 
extrapolate our findings to predict the longitudinal change of bone mass in these 
individuals over time. Thus, a prospective cohort study is required to determine whether, 
without any intervention, bone mass of these adolescents will be able to catch up to a 
normal range at the end of puberty as compared to that observed in their healthy peers, or 
if it will be worsened and progress to more severe bone disease such as osteoporosis or 
pathological fracture as they enter their adulthood. Moreover, a study exploring the 
within-person association between poor bone mass developed during adolescence and 
later osteoporosis experienced during adulthood is also important to provide healthcare 
providers and researchers with a better understanding of the trajectory of bone mass 




 Although this dissertation demonstrated several factors, both traditional and HIV-
specific, associated with reduced bone mass, we cannot infer causation from these 
associations due to the limitation of the study design. Additionally, since the pathogenesis 
of low bone mass in HIV-infected population is likely more complicated than that 
documented in general populations, the identification of the direct effects of each factor 
on bone mass deterioration may be challenging. Therefore, a prospective cohort study is 
an appropriate study design to provide more detailed information on causative factors of 
low bone mass among these adolescents. 
In this dissertation, we used DXA scan to measure bone mass in our adolescents. 
However, this DXA technique is based on the two-dimensional x-ray projected area of a 
three-dimensional structure, and thus DXA-derived BMD (areal BMD) is not a true 
volumetric measure [11]. This might allow us to underestimate BMD of each individual, 
and overestimate the extent of low bone mass problem in our population. Therefore, a 
future research may have to consider the alternative approaches, such as qCT or qMRI, 
for bone density measurements in order to avoid measurement errors. To date, the 
evidence on safety and efficacy of these procedures in children and adolescents remain 
limited. Furthermore, because of the other limitations of the DXA technique, including 
the requirement of calibration of the machine and well-trained technicians, lack of 
normative reference data for children and adolescents in low resource settings, cost of 
procedure and radiation exposure [11,17], the researchers may have to think carefully 
about surrogate markers which may be beneficial to screen for bone mass deterioration 
among this population. In addition, a study on the diagnostic accuracy of such markers is 




currently a standard procedure for measure bone mass in children and adolescents 
worldwide [11].  
The results of this dissertation demonstrated the possible detrimental effects of 
hypovitaminosis D and secondary hyperparathyroidism on bone turnover and bone mass, 
suggesting that the routine monitoring for vitamin D and PTH statuses in perinatally 
HIV-infected adolescents, especially in those who are at high risk for vitamin D 
deficiency, may be necessary. Future research on cost-effective analyses may be required 
to assure the utility and worthiness of these tests before implementation. Moreover, with 
the limitation of the study design of this dissertation, we cannot draw any firm 
conclusions on the benefits of vitamin D supplementation on bone health status of these 
individuals. The experimental study, particularly a randomized clinical trial, is the best 
approach to address this important research question as to whether vitamin D 
supplements is a potential preventive measure for bone demineralization in adolescents 
with hypovitaminosis D or VDI. The results obtained from this study will provide very 
meaningful scientific evidence to healthcare providers and public health practitioners, 
and may eventually have profound impact on the public health practice and policy. 
    
Final conclusions  
 Adverse bone health is an important NCD among HIV-infected adolescents with 
perinatally acquired HIV infection. Bone mass of these individuals is marked lower 
compared to their healthy peers. Apart from traditional risk factors, HIV-specific factors, 
dysregulated bone turnover and residual chronic immune activation and inflammation 




The routine monitoring of bone health status for individuals at high risk of low bone mass 
should be encouraged. The long-term follow up on the sequelae of poor bone mass, 
particularly osteoporosis and bone fracture, in their later decades of life are needed. 
Hypovitaminosis D is common in perinatally HIV-infected adolescents living in 
tropical countries. Several factors, both traditional and HIV-related factors, affect vitamin 
D status. The deficiency of vitamin D along with secondary hyperparathyroidism appears 
to be associated with abnormal bone turnover and bone demineralization in these 
individuals. The screening for vitamin D and PTH statuses may be helpful to identify 
individuals at high risk of having adverse bone health problem.   
In summary, with the changes of HIV epidemic in the ART era, this dissertation 
underscores an important non-AIDS-related comorbidity, adverse bone health, which is a 
new challenge facing adolescents living with HIV as they survive into adulthood. All 
information derived from this dissertation provide necessary scientific evidence which to 
help filling the gaps in current medical knowledge, raising the awareness among 
pediatricians and healthcare providers, allowing for a novel and well-designed study 
characterizing the problem, and, ultimately, tailored interventions to prevent the long-
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in Pediatric Infectious Diseases, including: bed side teaching about 
infectious diseases in the ward, outpatient clinic, and intensive care 
unit; service rounds in infectious disease ward; service at special 
clinic for HIV infected children; Service at special clinic for TB 
infected children 
  
 2010-present Clinical Researcher, Research Institute for Health Sciences, 
Chiang Mai University, Chiang Mai, Thailand 
 
Description of job: Conducting clinical research studies focusing 








 Society Membership 
 2004-present Member of the Medical Council of Thailand  
 
 2008-present        Member of the Royal College of Pediatricians of Thailand  
 
 2009-present Member of the Pediatric Infectious Diseases Society of Thailand 
 
 
HONORS AND AWARDS 
  
2004 First Class Honor, Doctor of Medicine, Chiang Mai University, 
Chiang Mai, Thailand 
 
2007 Fogarty International Clinical Scholarship, National Institute of 
Health, Bethesda, Maryland, United States 
 
2010 Young Investigator Awards, 17th Conference of Retrovirus and 
Opportunistic Infections, San Francisco, United States  
 
2010 Pediatric Infectious Disease Society of Thailand (PIDST) Paper 
Presentation Award (First), The Pediatric Infectious Diseases 
Society of Thailand 
  
2011  Ananda Mahidol Scholarship (King’s Scholarship) 
 
2012 Master tuition Scholarship, Johns Hopkins Bloomberg School of 
Public Health 
 
2014 Collaborative Initiative for Paediatric HIV Education and Research 
(CIPHER) Grant Award, International AIDS Society (IAS), 
Melbourne, Australia 
 
2014 The Best Researcher Award, Faculty of Medicine, Chiang Mai 
University 
 
2014 HIV Drug Therapy Glasgow Scholarship Award 
 
2015  IAS International Scholarship, Vancouver, Canada, July 2015 
 
2015 Collaborative Initiative for Paediatric HIV Education and 
Research (CIPHER) Travel Award, International AIDS Society 





2015 The Best Researcher Award, Faculty of Medicine, Chiang Mai 
University 
 
2016 Young Investigator Scholarship, 23rd Conference of Retrovirus 





 Journal Articles 
1. Seewijee T, Sudjaritruk T, Oberdorfer P. Atypical pneumonia: diagnosis and 
treatment. Thai J Pediatr 2009;48:193-9.  
 
2. Sudjaritruk T, Udompornwattana S, Gromrat P, Oberdorfer P. Relapse neonatal 
HSV infection: 1 case report. Thai J Pediatr 2009;48:325-31. 
 
3. Makonkawkeyoon K, Sudjaritruk T, Sirisanthana V, Silvilairat S. Fulminant 
enterovirus 71 infection: case report. Ann Trop Pediatr 2010:30:245-8. PMID: 
20828460. 
 
4. Sudjaritruk T, Sirisanthana T, Sirisanthana V. Antibody responses to hepatitis A 
virus vaccination in Thai HIV-infected children with immune recovery after 
antiretroviral therapy. Pediatr Inf Dis J 2011;30:256-9. PMID: 20856163. 
 
5. Sudjaritruk T, Sirisanthana V. Successful treatment of a child with vascular 
pythiosis. BMC Infect Dis 2011;11:33. PMID: 21276255. 
 
6. Phongsamart W, Sirisanthana V, Wittawatmongkol O, Maleesatharn A, 
Sudjaritruk T, Chearskul P, Aurpibul L, Sirisanthana T, Chokephaibulkit K. 
Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-
infected Thai children. Vaccine 2011;29:8705-11. PMID: 21893147. 
 
7. Sudjaritruk T, Oberdorfer P. Clinical characteristics and outcomes of Dengue-
infected children admitted to the Chiang Mai University Hospital during an 
outbreak in 2008. Chiang Mai Med J 2011;50:95-104.  
 
8. Sudjaritruk T, Sirisanthana T, Sirisanthana V. Immune reconstitution 
inflammatory syndrome from Penicillium marneffei in an HIV-infected child: A 
case report and review of literature. BMC Infect Dis 2012;12:28. PMID: 
22289885. 
 
9. Sudjaritruk T, Oberdorfer P, Puthanakit T, Sirisanthana T, Sirisanthana V. 
Causes of hospitalization among 1121 HIV-infected children: comparison of the 
pre-Pneumocystis jiroveci pneumonia prophylaxis, pre-antiretroviral therapy, and 





10. Cressey TR, Aurpibul L, Narkbunnam T, Sirisanthana V, Phongsamart W, 
Oberdorfer P, Lapphra K, Sudjaritruk T, Chokephaibulkit K. Pharmacological 
assessment of efavirenz weight-band dosing recommendations in HIV-infected 
Thai children. J Acquir Immune Defic Syndr 2013;62:e27-9. PMID: 23262981. 
 
11. Bunupuradah T, Puthanakit T, Fahey P, Kariminia A, Yusoff NK, Khanh TH, 
Sohn AH, Chokephaibulkit K, Lumbiganon P, Hansudewechakul R, Razali K, 
Kurniati N, Huy BV, Sudjaritruk T, Kumarasamy N, Fong SM, Saphonn V, 
Ananworanich J; TApHOD. Second-line protease inhibitor-based HAART after 
failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian 
HIV-infected children. Antivir Ther 2013;18:591-8. PMID: 23296119. 
 
12. Sudjaritruk T, Maleesatharn A, Prasitseubsai W, et al. Prevalence, 
characteristics, management and outcome of pulmonary tuberculosis in HIV-
infected children in the TREAT Asia Pediatric HIV Observational Database 
(TApHOD). AIDS Patient Care STDS 2013;27:649-56. PMID: 24206012. 
 
13. Aurpibul L, Cressey TR, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, 
Phongsamart W, Sudjaritruk T, Chokephaibulkit K. Efficacy, Safety and 
pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-
infected children using weight band dosing. Pediatr Inf Dis J 2015;34:392-7. 
PMID: 25760566. 
 
14. Aurpibul L, Puthanakit T, Sudjaritruk T, et al. The 10-year effectiveness of 
combination antiretroviral treatment in perinatally HIV-infected children 
participating in Thailand's National Access Program. Antivir Ther 2015 Jul 9. 
[Epub ahead of print]  PMID: 26158783. 
 
15. Sudjaritruk T, Puthanakit T. Adverse bone health among children and 
adolescents growing up with HIV. J Virus Erad 2015;1:159-67. 
 
16. Prasitsuebsai W, Kerr SJ, Truong KH, Ananworanich J, Do VC, Nguyen 
LV, Kurniati N, Kosalaraksa P, Sudjaritruk T, et al. Using lopinavir 
concentrations in hair samples to assess treatment outcomes on second-line 
regimens among Asian children. AIDS Res Hum Retroviruses 2015;31:1009-14. 
PMID: 26200586. 
 
17. Aurpibul L, Sricharoenchai S, Wittawatmongkol O, Sirisanthana V, Phongsamart 
W, Sudjaritruk T, Chokephaibulkit K. Vitamin D status in perinatally HIV-
infected Thai children receiving antiretroviral therapy. J Pediatr Endocrinol 
Metab 2015 Nov 13. [Epub ahead of print] PMID: 26565540. 
 
18. Boettiger DC, Sudjaritruk T, Nallusamy R, et al. Non-Nucleoside Reverse 
Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, 





19. Sudjaritruk T, Bunupuradah T, Aurpibul L, et al. Hypovitaminosis D and 
hyperparathyroidism: effects on bone turnover and bone mineral density among 
perinatally HIV-infected adolescents. AIDS 2016;30:1059-67. PMID: 26807972. 
 
20. Prasitsuebsai W, Teeraananchai S, Singtoroj T, Truong KH, Ananworanich J, Do 
VC, Nguyen LV, Kosalaraksa P, Kurniati N, Sudjaritruk T, et al. Treatment 
outcomes and resistance patterns of children and adolescents on second-line 
antiretroviral therapy in Asia. The manuscript has been accepted for publication in 




1. Sudjaritruk T, Aurpibul L, Sirisanthana V. Guideline for vaccination in Thai 
HIV-infected children. In: Kerdpanich A, Lohlekha R, Watanaveeradej V, 
Chotpitayasunon T, eds. Update on Pediatric Infectious Diseases 2009. Bangkok, 
2009:52-68. 
 
2. Sudjaritruk T, Oberdorfer P. What’s new in immunization for children and 
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 Fifth Year Medical Students 
 2008-2011 
 
 Pediatric Resident 
 2009-2011 (Graduated) 
  
 
 Classroom Instruction 
 Faculty of Medicine, Chiang Mai University 
 2008-2010 Fever with rash (319.491), Instructor, 250-280 fourth-year medical 
students  
 
 2008-2011 Dengue (331.504), Instructor, 250-280 fifth-year medical students 
 
 2008-2011 Streptococcal Infections (331.504), Instructor, 250-280 fifth-year 
medical students 
 
 2011 Immunization for Children and Adolescents (331.301), Instructor, 
250-280 third-year medical students 
 




 Other Significant Teaching 
 Johns Hopkins Bloomberg School of Public Health 
 2013 Principle of Epidemiology (340.601), Teaching Assistant, 60-70 

















National Research University, Chiang Mai University March 2015 to February 
2017  
Dr. Tavitiya Sudjaritruk, P.I. 
Effect of calcium and high-dose vitamin D supplementation on bone mineral density 
among perinatally HIV-infected children and adolescents 
 
CIPHER Grant Programme, IAS    August 2014 to July 2016 
Dr. Tavitiya Sudjaritruk, P.I. 
HIVNAT 203: Nonalcoholic fatty liver disease and long-term metabolic complications 
among perinatal HIV-infected children and adolescents receiving antiretroviral therapy. 
 
NIH/NIAID under The International Maternal  September 2009 to January 
Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2016 
Professor Sirisanthana, P.I. (Dr. Sudjaritruk, Investigator) 
IMPAACT 1077HS: HAART Standard Version of the PROMISE Study (Promoting 
Maternal and Infant Survival Everywhere). 
 
NIH/NIAID under The International Maternal  February 2011 to January 
Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2017 
Professor Sirisanthana, P.I. (Dr. Sudjaritruk, Investigator) 
IMPAACT P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, 
Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in 
Combination Regimens in HIV-1 Infected Infants, Children and Adolescents. 
 
NIH/NIAID under The International Maternal  September 2011 to August 
Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2018 
Professor Sirisanthana, P.I. (Dr. Sudjaritruk, Investigator) 
A5279: Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the 





2008-present Division of Infectious Diseases, Department of Pediatrics 
Faculty of Medicine, Chiang Mai University 












 Scientific Meetings 
2009  Successful treatment of vascular pythiosis: A case report (Oral 
Presentation), 67th Annual Pediatrics meeting, Chonburi, Thailand. 
 
2009 Causes of hospitalization in 880 HIV-infected children: effect of 
Thailand’s national antiretroviral access program (Poster), The 1st 
International Workshop on HIV Pediatrics, Cape Town, South Africa. 
 
2010 Causes of hospitalization in 1,112 HIV-infected children: comparison of 
the pre-Pneumocystis jiroveci pneumonia (PCP) prophylaxis, pre-
antiretroviral therapy, and antiretroviral therapy (ART) era (Poster), The 
17th Conference on Retroviruses and Opportunistic Infections, San 
Francisco, United States of America. 
 
2010  Antibody Responses to Hepatitis A Virus Vaccination in Thai HIV-
infected Children with Immune Recovery after Antiretroviral Therapy 
(Oral Presentation), The 14th Annual meeting of Pediatric Infectious 
Disease Society of Thailand, Chonburi, Thailand. 
 
2010 Antibody Responses to Hepatitis A Virus Vaccination in Thai HIV-
infected Children with Immune Recovery after Antiretroviral Therapy 
(Poster), The 2nd International Workshop on HIV Pediatrics, Vienna, 
Austria. 
 
2010  Antibody Responses to Hepatitis A Virus Vaccination in Thai HIV-
infected Children with Immune Recovery after Antiretroviral Therapy 
(Poster), XVIII International AIDS Conference, Vienna. 
 
2011 Five-Year Surveillance of antimicrobial-resistant pathogens among 
pediatric patients admitted to Chiang Mai University Hospital, Thailand 
(Poster), 8th International Symposium on Antimicrobial Agents and 
Resistance, Seoul, Korea. 
 
2011 Prevalence of antimicrobial resistance among gram-negative isolates in a 
pediatric intensive care unit at Chiang Mai University (Poster), 8th 
International Symposium on Antimicrobial Agents and Resistance, Seoul, 
Korea. 
 
2011  Second-line highly active antiretroviral therapy in Asian HIV-infected 






2012 24-week safety of tenofovir when administered according to weight band 
dosing in HIV-infected children > 15 kg as part of once-daily HAART 
regimen (Poster). ID week 2012, San Diego, United States of America. 
 
2013 48-week Safety of Tenofovir When Administered According to Weight 
Band Dosing in HIV-infected Children >/= 15 Kg as Part of a Once-daily 
HAART Regimen (Poster). The 20th Conference on Retroviruses and 
Opportunistic Infections, Atlanta, United States of America. 
 
2014 The 10-year Effectiveness of Highly Active Antiretroviral Treatment in 
Perinatally HIV-infected Children Participating in Thailand´s National 
Access Program (Poster). The 6th International Workshop on HIV 
Pediatrics, Melbourne, Australia. 
 
2014 The 10-year Effectiveness of Highly Active Antiretroviral Treatment in 
Perinatally HIV-infected Children Participating in Thailand´s National 
Access Program (Poster). The 20th International AIDS Conference, 
Melbourne, Australia. 
 
2015 Therapeutic Drug Monitoring of Lopinavir in HIV-infected Children on 
Second-line ART (Poster). The 22nd Conference on Retroviruses and 
Opportunistic Infections, Seattle, United States of America. 
 
2015 Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease 
and Liver Fibrosis among Perinatally HIV-infected Asian Adolescents 
(Oral Presentation). The 7th International Workshop on HIV Pediatrics, 
Vancouver, Canada. 
 
2015 Adverse Bone Health among Perinatally HIV-infected Asian Adolescents 
with Virological Suppression (Poster). The 7th International Workshop on 
HIV Pediatrics, Vancouver, Canada. 
 
2015 Higher 25-hydroxyvitamin D levels in perinatally HIV-infected Asian 
adolescents receiving boosted protease inhibitors (Poster). The 7th 
International Workshop on HIV Pediatrics, Vancouver, Canada. 
 
2015 Dysregulated Bone Remodeling but Stable Bone Mineral Density over 4-
year Tenofovir Disoproxil Fumarate Exposure among Perinatally HIV-
infected Asian Adolescents (Poster). The 7th International Workshop on 
HIV Pediatrics, Vancouver, Canada. 
 
2015  Prevalence of nonalcoholic fatty liver disease and liver fibrosis among 
perinatally HIV-infected Asian adolescents with history of transaminitis 
(Poster Discussion).  The 8th IAS Conference on HIV Pathogenesis, 





2016 Incidence of virologic rebound in perinatally HIV-infected adolescents on 
stable cART (Poster). The 23rd Conference on Retroviruses and 
Opportunistic Infections, Boston, United States of America. 
 
2016 Seroprevalence of Hepatitis B Among HIV-infected Children and 
Adolescents in Asia (Poster). The 23rd Conference on Retroviruses and 
Opportunistic Infections, Boston, United States of America. 
 
 
 Invited Seminars 
 2009 What’s in, What’s out in Pediatrics: What’s new in immunization for 
children and adolescents. Faculty of Medicine, Chiang Mai University, 
Chiang Mai, Thailand 
 
2009 Grand round: Why vaccinate? Faculty of Medicine, Chiang Mai 
University, Chiang Mai, Thailand 
 
2010 One day pediatrics conference: What’s new in the antimicrobial horizon? 
Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand 
 
2010 Speaker in Radio program (FM 100; Chiang Mai University): Dengue 
hemorrhagic fever  
 
2010  Speaker in Radio program (FM 100; Chiang Mai University): Hand-Foot 
and Mouth disease  
 
2010 Speaker in Television program (Channel 11): Dengue hemorrhagic fever: 
A dangerous disease 
 
2011 Antibiotics Smart Use: Antibiotics Smart Use: in pediatrics clinical 
practice. Faculty of Medicine, Chiang Mai University, Chiang Mai, 
Thailand 
 
2011 Current issues in adolescent immunization. Faculty of Medicine, Chiang 
Mai University, Chiang Mai, Thailand 
 
2011 Empirical carbapenems in severe pediatric infectious diseases: pro and 
con. Cha-Am, Petchburi, Thailand 
 
2011 Speaker in Radio program (FM 100; Chiang Mai University): E. coli 
outbreak  
 






2011 Speaker in Television program (Channel 11): Dengue hemorrhagic fever: 
A dangerous disease and prevention 
 
2014 Resurgence of measles outbreaks and challenges to disease eradication. 
Children’s hospital Los Angeles, Los Angeles, United States of America 
 
2015 Adverse bone health in HIV-infected adolescents. The 17th Bangkok 
International Symposium on HIV Medicine 2015, Bangkok, Thailand 
 
2015 Current practices and trends in paediatrics: Pediatric HIV infection: 
treatment update in general setting. Mae Ping Hotel, Chiang Mai, Thailand 
 
2015  Pediatric HIV infection: Update on Thai national treatment guidelines 






Brief description of research interests 
  Dr. Tavitiya Sudjaritruk is a pediatrician who specializes in infectious diseases. 
As a physician-researcher with broad-based training in pediatrics, infectious diseases, 
epidemiology and public health, she has focused my research areas of interest on 
HIV/AIDS among pediatric population. She has involved in many clinical research 
studies in both HIV-infected and HIV-affected children, such as prevention of maternal-
to-child transmission, pharmacokinetic profiles of new antiretroviral drugs, treatment 
failure and second-line therapy, vaccination and re-vaccination in HIV-infected children. 
Additionally, she has participated in the Therapeutic Research, Education and AIDS 
Training (TREAT) Asia Pediatric HIV Observational Database (TApHOD) research 
network since 2008, and currently is the site principle investigator of the Chiang Mai 
University pediatric site. She has conducted several clinical research studies focusing on 
the long-term, non-infectious medical complications (i.e., non-hepatitis liver disease, 
bone demineralization and metabolic syndrome) among perinatally HIV-infected children 




Pediatrics, Infectious Diseases, HIV infection, AIDS, Epidemiology, Antiretroviral 
therapy, Prevention maternal to child transmission (PMTCT), Vaccine, Immunization, 
Revaccination, Long-term complications of antiretroviral treatment. 
 
